



Article Synthesis of Bis(1,2,3-Triazole) Functionalized Quinoline-2,4-Diones[†]

David Milićević¹, Roman Kimmel¹, Martin Gazvoda², Damijana Urankar², Stanislav Kafka^{1,*} and Janez Košmrlj^{2,*}

- ¹ Department of Chemistry, Faculty of Technology, Tomas Bata University in Zlin, 760 01 Zlin, Czech Republic; david.milicevic@gmail.com (D.M.); r.kimmel@centrum.cz (R.K.)
- ² Faculty of Chemistry and Chemical Technology, University of Ljubljana, SI-1000 Ljubljana, Slovenia; martin.gazvoda@fkkt.uni-lj.si (M.G.); damijana.urankar@fkkt.uni-lj.si (D.U.)
- * Correspondence: kafka@utb.cz (S.K.); janez.kosmrlj@fkkt.uni-lj.si (J.K.); Tel.: +420-57-603-1115 (S.K.); +386-1-479-8558 (J.K.)
- + Dedicated to Professor Oldřich Paleta on his 80th birthday.

Received: 25 June 2018; Accepted: 4 September 2018; Published: 10 September 2018



Abstract: Derivatives of 3-(1*H*-1,2,3-triazol-1-yl)quinoline-2,4(1*H*,3*H*)-dione unsubstituted on quinolone nitrogen atom, which are available by the previously described four step synthesis starting from aniline, were exploited as intermediates in obtaining the title compounds. The procedure involves the introduction of propargyl group onto the quinolone nitrogen atom of mentioned intermediates by the reaction of them with propargyl bromide in *N*,*N*-dimethylformamide (DMF) in presence of a potassium carbonate and the subsequent formation of a second triazole ring by copper catalyzed cyclisation reaction with azido compounds. The products were characterized by ¹H, ¹³C and ¹⁵N NMR spectroscopy. The corresponding resonances were assigned on the basis of the standard 1D and gradient selected 2D NMR experiments (¹H–¹H gs-COSY, ¹H–¹³C gs-HSQC, ¹H–¹³C gs-HMBC) with ¹H–¹⁵N gs-HMBC as a practical tool to determine ¹⁵N NMR chemical shifts at the natural abundance level of ¹⁵N isotope.

Keywords: click chemistry; azido group; quinoline-2,4(1*H*,3*H*)-diones; propargyl group; bis(1,2,3-triazole)

1. Introduction

The 1,4-disubstituted-1,2,3-triazole heterocyclic motif has become an exceedingly popular structure finding applications in a broad range of areas including materials, biomaterials, metallopharmaceuticals, supramolecular chemistry, chemical sensing and catalysis, to name just a few [1]. In coordination and organometallic chemistry, for example, it became an important ligand scaffold, not only because of simplicity and reliability in its preparation, but also due to a variety of coordination modes offering [2–6]. Owing to the discovery of copper(I)-catalyzed 1,3-cycloaddition of terminal alkynes with organic azides, the CuAAC click reaction, the preparation of 1,4-disubstituted-1,2,3-triazole is facilitated in mild and modular fashion [7,8]. Although this "click triazole" has become a part of a broad range of molecules, its association with quinoline-2,4-diones remains largely underdeveloped. Apart from our recent publication on 3-(1*H*-1,2,3-triazole functionalized quinoline-2,4-diones are unprecedented.

As part of our endeavor in quinoline-2,4-dione chemistry [10] as well as functional click triazoles [11,12] and their applications [13], we became interested in the synthesis of bis(1,2,3-triazole) functionalized quinoline-2,4-diones **2** that may potentially serve as functional scaffolds in coordination

chemistry, molecular sensing and biochemistry. It is noteworthy that many compounds with the quinoline-2,4-dione structure were isolated from fungi, bacteria and plants, possessing broad range of interesting biological activities in vitro and in vivo [10]. Herein we report an approach to quinoline-2,4-diones unsymmetrically substituted with two click triazoles, an extensive ¹H, ¹³C, and ¹⁵N NMR spectral analyses, and a preliminary investigation of their chelating properties towards arene-ruthenium.



Figure 1. A general structure of 1,2,3-triazole quinoline-2,4-diones **1** (**left**) and the bis(1,2,3-triazole) counterparts **2** (**right**).

2. Results and Discussion

We reasoned that the desired bis(1,2,3-triazole) functionalized quinoline-2,4-diones **2** could be obtained via previously described 3-(1*H*-1,2,3-triazol-1-yl)quinoline-2,4(1*H*,3*H*)-dione derivatives **1** as synthetic intermediates (Scheme 1). The latter were prepared in a four-step reaction sequence starting from aniline, which upon treatment with diethyl 2-methylmalonate and diethyl 2-phenylmalonate initially afforded the corresponding 4-hydroxyquinolin-2(1*H*)-ones **3a** and **3b** [14]. Chlorination with sulfuryl chloride into 3-methyl- and 3-phenyl-3-chloroquinolin-2,4(1*H*,3*H*)-diones **4a** [15] and **4b** [16], followed by the nucleophilic displacement of the chlorine atoms with sodium azide, gave 3-methyl- and 3-phenyl- substituted 3-azidoquinoline-2,4(1*H*,3*H*)-diones **5a** and **5b** [16]. Then we began with copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC).



Scheme 1. Preparation of bis(1,2,3-triazole) functionalized quinoline-2,4-diones 2.

Although a large variety of reaction conditions have been developed for the CuAAC reaction [17,18], our previous work in this field has shown that for 3-azidoquinoline-2,4(1*H*,3*H*)-diones a combination of copper(II) sulfate pentahydrate and elemental copper (CuSO₄/Cu⁰) in dimethyl sulfoxide (DMSO) provided results that were superior to other combinations. Adopting those previous results in this work some additional optimizations of the reaction conditions were carried out with **5a** and phenylacetylene (**6a**) as the model substrates. Screening through the reaction solvents indicated that *N*,*N*-dimethylformamide (DMF) is even more efficient than DMSO, providing the desired target compound **1a** in shorter reaction times. The influence of the amount of granular copper to the course of the reaction between **5a** and equimolar amount of **6a** in DMF was also briefly investigated. While keeping the loading of CuSO₄·5H₂O constant at 10 mol % relative to **5a**, the amount of the elemental copper was varied from 380 mol % to 100 mol %. The results are summarized in Table **1**.

($ \begin{array}{c} $	E→Ph 6a CuSO ₄ MF, rt 1a	Ph
Entry	Cu ⁰ (mmol)	Reaction Time (h)	Yield ^b (%)
1	3.8	0.75	98
2	3	0.75	91
3	2	1	89
4	1	25	82 °

Table 1. The Effect of Granular Copper to the Conversion of 5a into 1a^a.

^a Reaction conditions: **5a** (1 mmol), phenylacetylene (1 mmol), and $CuSO_4 \cdot 5H_2O$ (0.1 mmol), DMF (4 mL), rt. The reaction time was determined by thin-layer chromatography (TLC) monitoring of the reaction mixture. ^b Refers to the yield of isolated pure product. ^c Complete consumption of **5a** was not reached.

Based on the above, in a general procedure, a mixture of 3-azidoquinoline-2,4(1*H*,3*H*)-dione (5, 1.0 mmol), a slight excess of terminal alkyne 6 (1.05 mmol), $CuSO_4 \cdot 5H_2O$ (0.12 mmol), and granular copper (2.0 mmol) in DMF (2.3 mL) was stirred at room temperature, in the presence of air. In addition to phenylacetylene (6a), propargyl alcohol (6b) was selected as the acetylene partner. The reactions were completed within 30 min. As indicated in Table 2, the products 1 were obtained in excellent yields. By using a more standard $CuSO_4 \cdot 5H_2O/L$ -ascorbic acid catalyst in $CH_2Cl_2/water$ biphasic system, the cycloaddition between 5a and 6a required substantially longer reaction time (48 h) to achieve a similar yield of the product 1a as compared to the above $CuSO_4/Cu^0/DMF$ conditions (Entries 1 and 2).

Table 2. Preparation of compounds 1.

		$N \rightarrow R^2$ $N \rightarrow R^2$ R^1 O				
Entry	Azide 5	R ¹	Acetylene 6	R ²	Product 1	Yield ^a
1	5a	Me	6a	Ph	1a	95
2	5a	Me	6a	Ph	1a	83 ^b
3	5b	Ph	6a	Ph	1b	86
4	5a	Me	6b	CH ₂ OH	1c	99
5	5b	Ph	6b	CH ₂ OH	1d	98

^a Refers to percent yield of pure (by TLC and IR) isolated product. ^b Employing $CuSO_4 \cdot 5H_2O/L$ -ascorbic acid/ CH_2Cl_2 /water conditions, 48 h reaction time.

Prior to the introduction of propargyl group at the N1 nitrogen atom of the quinoline-2,4(1*H*,3*H*)-dione ring in **1**, the primary hydroxyl groups at **1c** and **1d** were protected by acetylation by using acetic anhydride in pyridine as shown in Scheme 2. The corresponding acetates **1e** and **1f** were obtained in 84–85% yields.



Scheme 2. Preparation of compounds 1e and 1f.

Alkylation of compounds **1a**,**b**,**e**,**f** with propargyl group was carried out by using 1.5 equivalent of propargyl bromide (**6c**) and 3 equivalents of potassium carbonate in DMF. These reactions proceeded smoothly within 45 min at room temperature. The yields are given in Table 3.

	$ \begin{array}{c} 0 \\ N \\ N \\ N \\ N \\ N \\ 0 \\ H \\ 1 \end{array} $	≻R ²	GC K ₂ CO ₃ DMF, rt	γ			
Entry	1	R ¹	R ²	6	Yield of 7 (%) ^a		
1	1a	Me	Ph	6c	7a , 96		
2	1b	Ph	Ph	6c	7b , 79		
3	1e	Me	CH ₂ OAc	6c	7 c, 81		
4	1f	Ph	CH ₂ OAc	6c	7d , 63		

Table 3. Preparation of compounds 7.

^a Refers to percent yield of pure (by TLC and IR) isolated product.

Although *N*-alkylation of the lactam group usually takes place preferentially in quinoline-2,4(1*H*,3*H*)-diones [10], the competitive *O*-alkylation has been documented in similar systems [19]. The N1 position of thus introduced propargyl group in 7 was confirmed by 2D NMR spectroscopy in particular by the presence of the long-range correlations between the propargyl methylene protons and carbon atoms C-8a and C-2 in the ¹H-¹³C HMBC spectra (in **7a**,**c**,**d**) as well as N1 nitrogen atom in the ¹H-¹⁵N gs-HMBC spectrum (in **7a**).

As the last step of the reaction sequence shown in Scheme 1, monotriazoles 7 were submitted to a second cycloaddition with selected azides 8 to give the expected bis-triazoles 2. Benzyl azide (8a), azidobenzene (8b) and tetrazolo[1,5-*a*]pyridine (8c) were selected as the reaction partners. Whereas benzyl azide (8a) and azidobenzene (8b) readily reacted into the desired products 2a,b,d,e,g,h,j,k at room temperature, tetrazolo[1,5-*a*]pyridine (8c), a synthetic equivalent for 2-azidopyridine (8c'), required harsher reaction conditions (Table 4). This can be explained by the tetrazolyl form in which compound 8c exists predominantly at room temperature [11]. As the proportion of the azido isomer increases at elevated temperature, the reactions with 8c were conducted at 100 °C, to afford compounds 2c,f,i,l in good yields.

In this case too, some standard click catalyst/solvent combinations were briefly evaluated. The cycloaddition between acetylene **7c** and benzyl azide (**8a**) with CuSO₄·5H₂O/Na-ascorbate (or L-ascorbic acid) pair in CH₂Cl₂/water and *t*-BuOH/water solvent systems required prolonged reaction times, providing lower yields of the product **2d** as compared to the CuSO₄/Cu⁰/DMF conditions (compare Entries 4–7). In the case of *t*-BuOH/water the presence of water in the reaction mixture turned the reactants and products into a gummy material that stuck to the reaction vessel and the magnetic stirring bar, impeding the reaction from going to completion, as already noticed for click reactions with highly hydrophobic reagents [20].

In principle, the "click-propargylation-click" reaction sequence at 3-azidoquinoline-2,4-diones 5 could be altered, providing the target bis-(1,2,3-triazole) functionalized products 2 via bifunctional azidoethynyl quinoline-2,4-dione intermediate 9 as shown in Scheme 3. This would allow orthogonal sequential synthetic strategies for accessing bis(1,2,3-triazole) functionalized materials [21]. We briefly explored this possibility by treating 3-azido-1-propargylquinoline-2,4-dione derivative 9a with phenylacetylene (6a) or benzyl azide (8a) under the above mentioned $CuSO_4/Cu^0/DMF$ conditions. The corresponding monotriazoles 7a (16%) and 10a (42%), respectively, were obtained in moderate yields.

Ņ^{≂N} N^{⊊N} R R^3-N_3 8 R¹ Ŕ Cu⁰, CuSO₄ ò ò DMF -R³ 'n≈n 7 2 synthetic equivalent for N₃ ٧a N₃ 8a 8b 8c 8c' R² Entry 2 \mathbb{R}^1 R³ t (°C) Time (h) Yield ^a (%) 1 Me Ph Bn 23 1 97 а 2 b Me Ph Ph 23 1 99 3 100 с Me Ph 2-Py 0.5 93 CH₂OAc 4 d Me Bn 23 0.5 96 85^{b} 5 d Me CH₂OAc Bn 23 4 81 ^c 6 d Me CH₂OAc Bn 23 48 45 ^d 7 CH₂OAc 23 d Me Bn 45 CH₂OAc 8 Me Ph 23 2 92 e 9 100 f Me CH₂OAc 2-Py 1 85 10 92 g Ph Ph Bn 23 1 23 11 h Ph Ph Ph 1 94 100 12 i Ph Ph 2-Py 0.75 57 13 CH₂OAc Bn 23 2 97 j Ph 14 k Ph CH₂OAc Ph 23 0.5 93 15 1 Ph CH₂OAc 2-Py 100 0.5 85

^a Refers to percent yield of pure (by TLC and IR) isolated product. ^b Employing $CH_2Cl_2/water/CuSO_4\cdot 5H_2O/Na-ascorbate conditions. ^c Employing$ *t* $-BuOH/water/CuSO_4\cdot 5H_2O/Na-ascorbate conditions. ^d Employing$ *t* $-BuOH/water/CuSO_4\cdot 5H_2O/L-ascorbic acid conditions.$



Scheme 3. An alternative approach to bis(1,2,3-triazole) functionalized quinoline-2,4-diones **2** through a "propargylation-click-click" reaction sequence.

The compounds **2a–1** were characterized by ¹H, ¹³C and, with the exception of **2a**,*g*,*h*, also by ¹⁵N NMR spectroscopy. The corresponding resonances were assigned on the basis of gradient-selected 2D NMR experiments including ¹H–¹H *gs*-COSY, ¹H–¹³C *gs*-HSQC, ¹H–¹³C *gs*-HMBC and ¹H–¹⁵N *gs*-HMBC. For the atom numbering scheme, see Figure 2. Some characteristic spectral features are discussed below.

Table 4. Preparation of compounds 2.



Figure 2. Selected ring and atom numbering along with the chemical shift data (mean values rounded up to whole numbers are provided).

The ${}^{13}C$ and ${}^{15}N$ chemical shifts for triazole rings **A** and **D** (Tables 5 and 6) are in a good agreement with those reported previously [11].

To preliminarily assess the applicability of bis-triazole compounds **2** as ligands, we decided to examine their coordination abilities to arene-ruthenium. NMR experiment was designed in which compound **2b** and equimolar amount of ruthenium (0.5 equiv of $[RuCl(\mu-Cl)(\eta^6-p-cymene)]_2$) were mixed in CDCl₃ in NMR tube at room temperature. CDCl₃ was selected as the reaction solvent in place of the coordinative DMSO- d_6 to avoid possible interference with the metal center (Scheme 4). The reaction mixture was monitored by time dependent ¹H NMR spectroscopy indicating an instant change in the resonances for **2b** and *p*-cymene ligands upon mixing to form a new set of resonances that remained unchanged over several days. As shown in Figures 3 and 4, both proton and carbon NMR resonances were severely broadened suggesting the presence of a dynamic process in the solution, presumably an equilibrium with the starting ligand, which can result from a relatively weak ligand-to-metal interaction. Unfortunately, broad NMR resonances prevented an unambiguous structure determination of the product [Ru–Cym]-2b through the 2D NMR techniques due to overlap as well as lack of several indicative crosspeaks in the spectra, especially in ¹H-¹⁵N gs-HMBC. Nevertheless, the analysis of the available NMR data tentatively suggested the coordination of both 1,2,3-triazole rings to the Ru–Cym unit as indicated in Scheme 4. Although the coordination properties of the 1,2,3-triazole nitrogen atom N2 are weak, some of us have previously shown that such chelates can be greatly stabilized through an assistance of auxiliary ligand [22].

	1a	1b	1c	1d	7a	7b	7c	7d
Quinolone								
N1	_	-	-	-	-	-	134.4	-
C2	168.5	166.8	168.7	166.8	167.7	165.8	167.8	165.8
C3	72.2	80.0	71.9	79.7	72.6	79.6	72.8	80.0
C4	190.7	188.9	190.8	189.0	189.7	187.5	189.6	187.7
C4a	117.4	119.2	117.5	119.2	119.0	121.0	119.2	120.9
C5	127.7	127.6	127.6	127.5	128.2	129.2	128.0	127.8
C6	123.5	123.5	123.3	123.4	124.2	124.6	124.0	124.2
C7	137.3	137.0	137.1	136.9	137.3	136.9	137.1	136.7
C8	117.0	116.7	116.9	116.7	116.7	115.8	116.6	116.3
C8a	141.6	140.5	141.6	140.6	140.8	140.6	140.7	140.0
Ring A								
NIA	_	-	-	-	-	-	247.9	-
N2 ^A	_	-	-	-	-	-	363.4	_
N3 ^A	_	-	-	-	-	-	354.0	_
C4 ^A	145.8	145.3	147.4	146.8	145.9	146.0	141.5	140.9
C5 ^A	122.4	123.4	123.7	124.8	122.5	122.3	126.0	127.1
H5 ^A	8.89	8.49	8.26	7.77	8.89	7.26	8.46	8.15

Table 5. Selected ¹H, ¹³C and ¹⁵N NMR chemical shifts in ppm for compounds 1 and 7.

	2a	2b	2c	2d	2e	2f	2g	2h	2i	2j	2k	21
Quinolone												
N1	-	136.3	135.8	138.7	138.7	135.3	-	-	137.5	140.4	140.4	138.9
C2	168.2	168.3	168.5	168.2	168.3	168.6	166.2	166.4	166.6	166.6	166.9	166.6
C3	72.8	73.0	73.0	71.6	71.5	73.3	80.1	80.3	80.4	79.6	79.6	79.7
C4	190.0	190.0	189.9	189.4	189.4	189.9	188.2	188.2	188.1	187.9	187.9	187.9
C4a	119.1	119.2	119.3	119.2	119.2	119.4	120.9	120.9	120.9	120.9	120.9	121.0
C5	128.1	128.1	128.1	129.3	129.4	127.9	127.9	127.9	127.9	129.0	129.1	129.1
C6	123.9	124.0	123.9	124.6	124.7	123.8	124.0	124.1	124.0	124.6	124.7	124.6
C7	137.2	137.3	137.2	137.8	137.8	137.0	136.8	136.8	136.8	137.2	137.4	137.2
C8	116.7	116.8	116.6	116.9	116.8	116.5	116.7	116.7	116.5	116.8	116.7	116.6
C8a	141.5	141.6	141.4	141.7	141.7	141.3	140.8	140.7	140.5	141.1	140.9	141.2
Ring A												
N1 ^A	_	248.9	248.9	248.4	248.8	247.6	_	_	248.7	249.8	249.9	249.7
N2 ^A	_	363.2	363.4	361.6	_	363.7	_	_	367.4	365.1	_	_
N3 ^A	_	347.1	347.1	355.2	355.5	353.4	_	_	347.2	356.9	357.2	357.1
C4 ^A	145.9	146.0	146.0	142.3	142.3	141.6	145.4	145.4	145.4	140.9	140.9	140.9
C5 ^A	122.5	122.5	122.5	124.2	124.1	126.1	123.4	123.5	123.4	126.4	126.4	126.4
H5 ^A	8.87	8.87	8.87	7.78	7.86	8.47	8.51	8.54	8.58	7.08	7.14	7.13
Ring D												
N1 ^D	_	255.7	260 5	250.4	256.3	260.0	_	_	260.4	250.4	256.3	261.2
N2D	_	358.1	358.6	362.6		361.9	_	_		362.9		
N3 ^D	_	353.4	356.9	350.0	351.9	356.5	_	_	357 7	350.5	352.9	355.8
$C4^{\rm D}$	142.2	143.3	143.2	142.9	143.2	143.2	141 9	142 9	143.0	142.9	143.2	143.0
$C5^{D}$	123.8	121.8	120.6	123.5	121 7	120.6	124.2	122.3	120.8	123.5	121.8	121.0
H5D	816	8 75	8.82	7 55	8 10	8.82	8 24	8.83	8.81	7.58	8.05	8.63
110	0.10	0.70	0.04		0.10	0.02	0.21	0.00	0.01	1.00	0.00	0.00

Table 6. Selected ¹H, ¹³C and ¹⁵N NMR chemical shifts in ppm for compounds 2.



Scheme 4. Reaction of 2b with $[RuCl(\mu-Cl)(\eta^6-p-cymene)]_2$ with tentatively proposed structure of the [Ru-Cym]-2b complex.



Figure 3. Aromatic region of ¹H NMR spectra of: (a) **2b** in CDCl₃, and (b) a mixture of **2b** (42 mM) and $[RuCl(\mu-Cl)(\eta^6-p-cymene)]_2$ (21 mM) in CDCl₃ immediately after dissolution.



Figure 4. Aromatic region of ¹³C NMR spectra of: (a) **2b** in CDCl₃, and (b) a mixture of **2b** (42 mM) and $[RuCl(\mu-Cl)(\eta^6-p-cymene)]_2$ (21 mM) in CDCl₃.

Attempts to unambiguously determine the structure of [Ru–Cym]-**2b** by variable temperature NMR techniques, as well as to grow crystals suitable for X-ray, failed. All of the above also applies to compounds **2g** and **2h** that were also preliminarily tested in [Ru–Cym] coordination.

3. Materials and Methods

3.1. General Experimental Methods

The reagents and solvents were used as obtained from the commercial sources. Compounds 3a [14], 3b [14], and 5b [15], as well as benzyl azide (8a) [23], azidobenzene (8b) [11], and tetrazolo[1,5-a]pyridine (8c) [24] were prepared as described in the literature. Column chromatography was carried out on Fluka Silica gel 60 (particle size 0.063-0.2 mm, activity acc. Brockmann and Schodder 2–3). Melting points were determined on the microscope hot stage, Kofler, PolyTherm, manufacturer Helmut Hund GmbH, Wetzlar and are uncorrected. TLC was carried out on pre-coated TLC sheets ALUGRAM[®] SIL G/UV₂₅₄ for TLC, MACHEREY-NAGEL. NMR spectra were recorded with a Bruker Avance III 500 MHz NMR instrument operating at 500 MHz (¹H), 126 MHz (^{13}C) and 51 MHz (^{15}N) at 300 K. Proton spectra were referenced to TMS as internal standard, in some cases to the residual signal of DMSO- d_5 (at δ 2.50 ppm) or CHCl₃ (at δ 7.26 ppm). Carbon chemical shifts were determined relative to the ${}^{13}C$ signal of DMSO- d_6 (39.52 ppm) or CDCl₃ (77.16 ppm). 15 N chemical shifts were extracted from $^{1}H^{-15}N$ gs-HMBC spectra (with 20 Hz digital resolution in the indirect dimension and the parameters adjusted for a long-range ¹H–¹⁵N coupling constant of 5 Hz) determined with respect to external nitromethane and are corrected to external ammonia by addition of 380.5 ppm. Nitrogen chemical shifts are reported to one decimal place as measured of the spectrum, however, the data should not be considered to be more accurate than ± 0.5 ppm because of the digital resolution limits of the experiment. Chemical shifts are given on the δ scale (ppm). Coupling constants (*J*) are given in Hz. Multiplicities are indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) or br (broadened). Infrared spectra were recorded on FT-IR spectrometer Alpha (Bruker Optik GmbH Ettlingen, Ettlingen, Germany) using samples in potassium bromide disks and only the strongest/structurally most important peaks are listed. Electron impact mass spectra (EI) were recorded on a Shimadzu QP-2010 instrument at 70 eV. HRMS spectra were recorded with Agilent 6224 Accurate Mass TOF LC/MS system with electrospray ionization (ESI). Elemental analyses (C, H, N) were performed with FlashEA1112 Automatic Elemental Analyser (Thermo Fisher Scientific Inc., Waltham, MA, USA).

3.2. General Procedure for the Synthesis of 3-Chloroquinoline-2,4(1H,3H)-Diones 4 (Scheme 1)

The 3-Chloroquinoline-2,4(1*H*,3*H*)-diones **4a** [15] and **4b** [16], were prepared from 4-hydroxyquinolin-2(1*H*)-ones **3a** [14] and **3b** [14], respectively, according to the procedures described in the literature.

3-Chloro-3-methylquinoline-2,4(1*H*,3*H*)-dione (4a). Compound 4a (19.71 g, 94.0 mmol, 94%) was prepared from **3a** (17.52 g, 100 mmol). Yellow crystals, m.p. 178–181 °C (benzene), m.p. [15] 172 °C (acetic acid—water); $R_f = 0.52$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 1.99 (s, 3H), 7.06 (d, 1H, *J* = 8.0 Hz), 7.22 (dd, 1H, *J* = 7.6, 7.6 Hz), 7.59–7.66 (m, 1H), 8.02 (d, 1H, *J* = 7.7 Hz), 9.41 (s, 1H); ¹³C NMR (126 MHz, CDCl₃) δ 21.2, 62.8, 116.7, 118.1, 124.5, 129.1, 136.8, 139.6, 169.2, 188.4; IR (cm⁻¹): ν 3203, 3072, 3004, 2940, 1709, 1674, 1614, 1600, 1486, 1439, 1379, 1239, 770, 440; MS (EI) *m/z* (%): 212 (4, [M + 3]⁺), 211 (33, [M (³⁷Cl)]⁺), 210 (17, [M + 1]⁺), 209 (100, [M (³⁵Cl)]⁺), 208 (18), 175 (15), 174 (36), 146 (68), 128 (17), 120 (18), 119 (59), 92 (32), 91 (15); HRMS (ESI+): *m/z* calcd for C₁₀H₉ClNO₂⁺ [M + H]⁺ 210.0316, found 210.0313. Anal. Calcd for C₁₀H₈ClNO₂ (209.63): C, 57.30; H, 3.85; N, 6.68%. Found: C, 57.18; H, 3.83; N, 6.61%.

3-Chloro-3-phenylquinoline-2,4(1*H*,3*H*)-dione (4b). Compound 4b (26.08 g, 96.0 mmol, 96%) was prepared from 3b (23.73 g, 100 mmol). Pale yellow needles, m.p. 182–185 °C (benzene), m.p. [16] 178–180 °C (ethanol); $R_f = 0.57$ (30% ethyl acetate in chloroform). ¹H NMR (500 MHz, CDCl₃) δ 7.04 (d, 1H, J = 8.0 Hz, H-8), 7.18 (ddd, 1H, J = 7.8, 7.4, 0.7 Hz, H-6), 7.33–7.39 (m, 3H, H-3^C, H-4^C, H-5^C), 7.51–7.54 (m, 2H, H-2^C, H-6^C), 7.55 (ddd, 1H, J = 7.3, 6.5, 1.5 Hz, H-7), 7.97 (dd, 1H, J = 7.8, 1.2 Hz, H-5), 9.82 (s, 1H, H-1); ¹³C NMR (126 MHz, CDCl₃) δ 74.9 (C-3), 116.9 (C-8), 118.7 (C-4a), 124.7 (C-6), 127.4 (C-2^C, C-6^C), 129.1 (C-5), 129.2 (C-3^C, C-5^C), 129.8 (C-4^C), 134.6 (C-1^C), 137.0 (C-7), 139.4 (C-8a), 168.8 (C-2), 187.9 (C-4); IR (cm⁻¹): ν 3201, 3138, 3082, 2992, 2926, 1716, 1680, 1613, 1595, 1485, 1365, 755, 743, 690; MS (EI) m/z (%): 273 (7, [M (³⁷Cl)]⁺), 271 (21, [M (³⁵Cl)]⁺), 238 (12), 237 (80), 236 (100), 218 (10), 120 (63), 119 (19), 92 (34), 89 (10), 77 (12), 76 (10), 65 (14), 63 (10); HRMS (ESI+): m/z calcd for C₁₅H₁₁ClNO₂⁺ [M + H]⁺ 272.0473, found 272.0480. Anal. Calcd for C₁₅H₁₀ClNO₂ (271.70): C, 66.31; H, 3.71; N, 5.16%. Found: C, 66.07; H, 3.62; N, 5.29%.

3.3. General Procedure for the Synthesis of 3-Azidoquinoline-2,4(1H,3H)-Diones 5 (Scheme 1)

To a stirred solution of the 3-chloroquinoline-2,4(1*H*,3*H*)-dione 4 (40 mmol) in DMF (200 mL), sodium azide (3.90 g, 60 mmol) was added in small portions during 10 min. The reaction mixture was stirred in darkness for additional 2 h and then poured into ice-water (1.5 L). The precipitated solid was filtered, washed with water and dried at 50 °C in darkness, which afforded product **5**, pure according to TLC and ¹H NMR spectrum, which was crystallized from benzene.

3-Azido-3-methylquinoline-2,4(1H,3H)-dione (5a). Compound **5a** (8.47 g, 39.2 mmol, 98%) was prepared from **4a** (8.39 g, 40.0 mmol). Colorless needles, m.p. 158–161 °C (benzene, 87% yield of recrystallization); $R_f = 0.30$ (30% ethyl acetate in chloroform). ¹H NMR (500 MHz, CDCl₃) δ 1.86 (s, 3H, CH₃), 7.11 (d, 1H, *J* = 8.0 Hz, H-8), 7.22 (dd, 1H, *J* = 7.4, 7.4 Hz, H-6), 7.60–7.67 (m, 1H, H-7), 7.98 (d, 1H, *J* = 7.3 Hz, H-5), 9.86 (s, 1H, H-1); ¹³C NMR (126 MHz, CDCl₃) δ 23.6 (CH₃), 70.0 (C-3), 116.9 (C-8), 118.0 (C-4a), 124.6 (C-6), 128.6 (C-5), 137.2 (C-7), 140.0 (C-8a), 171.6 (C-2), 191.7 (C-4); IR (cm⁻¹): ν 3202, 3078, 3005, 2936, 2108, 1708, 1682, 1614, 1598, 1485, 1392, 1284, 1156, 755, 612; MS (EI) *m/z* (%): 217 (0.24, [M + 1]⁺), 216 (2, [M]⁺), 147 (15), 120 (11), 119 (100), 92 (35), 91 (11), 64 (12); HRMS (ESI+): *m/z* calcd for C₁₀H₉N₄O₂⁺ [M + H]⁺ 217.0720, found 217.0724. Anal. Calcd for C₁₀H₈N₄O₂ (216.20): C, 55.55; H, 3.73; N, 25.91%.

3-Azido-3-phenylquinoline-2,4(1*H***,3***H***)-dione (5b). Compound 5b (10.90 g, 39.2 mmol, 98%) was prepared from 4b (10.87 g, 40.0 mmol). Colorless needles, m.p. 186–189 °C (benzene, 96% yield of recrystallization); m.p. [9] 173–181 °C (benzene); R_f = 0.33 (38% ethyl acetate in petroleum ether); ¹H NMR (500 MHz, CDCl₃) \delta 6.98 (d, 1H, J = 8.1 Hz, H-8), 7.16 (dd, 1H, J = 7.6, 7.6 Hz, H-6), 7.38–7.43 (m, 3H, H-3^C, H-4^C, H-5^C), 7.48–7.53 (m, 2H, H-2^C, H-6^C), 7.54 (ddd, 1H, J = 7.7, 7.7, 1.6 Hz, H-7),**

10 of 21

7.93 (dd, 1H, *J* = 7.8, 1.6 Hz, H-5), 9.30 (s, 1H, H-1); ¹³C NMR (126 MHz, CDCl₃) δ 78.0 (C-3), 116.7 (C-8), 119.5 (C-4a), 124.6 (C-6), 127.3 (C-2^C, C-6^C), 128.6 (C-5), 129.8 (C-3^C, C-5^C), 130.4 (C-4^C), 132.6 (C-1^C), 136.9 (C-7), 139.4 (C-8a), 170.2 (C-2), 189.9 (C-4); ¹⁵N NMR (51 MHz, CDCl₃) δ 133.4 (N-1); IR (cm⁻¹): ν 3244, 2105, 1718, 1705, 1685, 1611, 1484, 1356, 1256, 877, 773, 744, 702, 611, 525; MS (EI) *m/z* (%): 250 (7, [M - N₂]⁺), 236 (8, [M - N₃]⁺), 147 (28), 120 (14), 119 (100), 104 (15), 92 (32), 77 (10), 76 (10), 64 (14); HRMS (ESI+): *m/z* calcd for C₁₅H₁N₂O₂⁺ [M - N₂ + H]⁺ 251.0815, found 251.0818. HRMS (ESI-): *m/z* calcd for C₁₅H₉N₄O₂⁻ [M - H]⁻ 277.0731, found 277.0732; calcd for C₁₅H₉N₂O₂⁻ [M - N₂ - H]⁻ 249.0670, found 249.0671. Anal. Calcd for C₁₅H₁₀N₄O₂ (278.27): C, 64.74; H, 3.62; N, 20.13%. Found: C, 64.54; H, 3.56; N, 20.38%.

3.4. General Procedure for the Synthesis of 3-(1H-1,2,3-Triazol-1-yl)Quinoline-2,4(1H,3H)-Diones 1a–d by Employing CuSO₄/Cu⁰/DMF Conditions (Table 2, Entries 1 and 3–5)

A solution of phenylacetylene (**6a**) (1.287 g, 12.6 mmol) or propargyl alcohol (**6b**) (706 mg, 12.6 mmol) in DMF (4 mL) was added dropwise to a vigorously stirred mixture of 3-azidoquinoline-2,4(1*H*,3*H*)-dione **5** (12 mmol), CuSO₄·5H₂O (300 mg, 1.2 mmol), granular copper (1.5 g, 24 mmol) and DMF (24 mL). The reaction mixture was stirred in darkness for 30 min. Afterward, (NH₄)₂CO₃ (3.5 g, 36 mmol) and water (12 mL) were added to the resulting brown-black suspension and the stirring was continued for 10 min. The reaction mixture was subjected to column chromatography with silica gel (15 g, column diameter of 1 cm) as a stationary phase, and 10% ethanol in chloroform as a mobile phase. Combined fractions containing yellow eluate were washed with saturated aqueous NH₄Cl (5 × 50 mL), dried (Na₂SO₄), and concentrated under reduced pressure to afford pure products **1a–d**, which were recrystallized from ethanol for analyses.

3-Methyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline-2,4(1H,3H)-dione (1a). Colorless solid, m.p. 217–219 °C (ethanol); $R_f = 0.35$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.15 (s, 3H, CH₃), 7.22–7.27 (m, 2H, H-6, H-8), 7.33–7.39 (m, 1H, H-4^B), 7.45–7.50 (m, 2H, H-3^B, H-5^B), 7.73–7.79 (m, 1H, H-7), 7.83–7.90 (m, 3H, H-5, H-2^B, H-6^B), 8.89 (s, 1H, H-5^A), 11.48 (s, 1H, H-1); ¹³C NMR (126 MHz, DMSO- d_6) δ 23.1 (CH₃), 72.2 (C-3), 117.0 (C-8), 117.4 (C-4a), 122.4 (C-5^A), 123.5 (C-6), 125.1 (C-2^B, C-6^B), 127.7 (C-5), 128.0 (C-4^B), 129.0 (C-3^B, C-5^B), 130.6 (C-1^B), 137.3 (C-7), 141.6 (C-8a), 145.8 (C-4^A), 168.5 (C-2), 190.7 (C-4); IR (cm⁻¹): ν 3137, 2911, 1714, 1683, 1612, 1483, 1430, 1386, 1355, 1238, 1023, 808, 759, 690, 594; MS (EI) m/z (%): 319 (2, [M + 1]⁺), 318 (8, [M]⁺), 117 (14), 116 (100), 102 (12), 89 (14); HRMS (ESI+): m/z calcd for C₁₈H₁₅N₄O₂⁺ [M + H]⁺ 319.1190, found 319.1188. Anal. Calcd for C₁₈H₁₄N₄O₂ (318.33): C, 67.91; H, 4.43; N, 17.60%. Found: C, 67.80; H, 4.47; N, 17.89%.

3-Phenyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline-2,4(1H,3H)-dione (1b). Colorless solid, m.p. 280–283 °C (ethanol); m.p. [9] 274–277 °C (ethanol); $R_{\rm f} = 0.37$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 7.12 (d, 1H, J = 8.1 Hz, H-8), 7.16–7.20 (m, 1H, H-6), 7.31–7.37 (m, 1H, H-4^B), 7.40–7.47 (m, 4H, H-3^B, H-5^B, H-2^C, H-6^C), 7.49–7.55 (m, 3H, H-3^C, H-4^C, H-5^C), 7.62–7.67 (m, 1H, H-7), 7.80–7.84 (m, 2H, H-2^B, H-6^B), 7.86 (dd, 1H, J = 7.8, 1.4 Hz, H-5), 8.49 (s, 1H, H-5^A), 11.68 (s, 1H, H-1); ¹³C NMR (126 MHz, DMSO- d_6) δ 80.0 (C-3), 116.7 (C-8), 119.2 (C-4a), 123.4 (C-5^A), 123.5 (C-6), 125.2 (C-2^B, C-6^B), 127.6 (C-5), 128.0 (C-4^B), 128.9 (C-2^C, C-6^C), 129.0 (C-3^B, C-5^B), 129.6 (C-3^C, C-5^C), 129.9 (C-1^C), 130.5 (C-1^B), 130.6 (C-4^C), 137.0 (C-7), 140.5 (C-8a), 145.3 (C-4^A), 166.8 (C-2), 188.9 (C-4); IR (cm⁻¹): ν 3275, 3169, 1721, 1690, 1613, 1595, 1486, 1452, 1353, 854, 771, 756, 699, 666, 607; MS (EI) m/z (%): 381 (2, [M + 1]⁺), 380 (8, [M]⁺), 247 (13), 237 (15), 236 (56), 220 (13), 218 (13), 120 (11), 117 (10), 116 (100), 102 (15), 92 (10), 89 (15), 77 (14); HRMS (ESI+): m/z calcd for C₂₃H₁₇N₄O₂⁺ [M + H]⁺ 381.1346, found 381.1341. Anal. Calcd for C₂₃H₁₆N₄O₂ (380.40): C, 72.62; H, 4.24; N, 14.73%. Found: C, 72.40; H, 4.23; N, 14.90%.

3-(4-(Hydroxymethyl)-1H-1,2,3-triazol-1-yl)-3-methylquinoline-2,4(1H,3H)-dione (1c). Colorless solid, m.p. 188–189 °C (ethanol); $R_{\rm f} = 0.35$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.08 (s, 3H, CH₃), 4.55 (d, 2H, J = 5.6 Hz, CH₂), 5.28 (t, 1H, J = 5.6 Hz, OH), 7.18–7.25 (m, 2H, H-6, H-8), 7.69–7.76 (m, 1H, H-7), 7.83 (dd, 1H, J = 8.1, 1.4 Hz, H-5), 8.26 (s, 1H, H-5^A), 11.39 (s, 1H, 1-7), 7.83 (dd, 2H, J = 8.1, 2H, H-6, H-8), 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 2H, H-7), 8.26 (s, 2H, H-5^A), 11.39 (s, 2H, H-6, H-8), 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 2H, H-7), 8.26 (s, 2H, H-5^A), 11.39 (s, 2H, H-6, H-8), 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 2H, H-7), 8.26 (s, 2H, H-5^A), 11.39 (s, 2H, H-6, H-8), 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 1.4 Hz, H-7), 8.26 (s, 2H, H-5^A), 11.39 (s, 2H, H-6, H-8), 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 1.4 Hz, H-7), 8.26 (s, 2H, H-5^A), 11.39 (s, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.83 (dd, 2H, J = 8.1, 7.69–7.76 (m, 2H, H-7), 7.89–7.25 (m, 2H, H-7), 7.89–7.2

H-1); 13 C NMR (126 MHz, DMSO- d_6) δ 23.1 (CH₃), 55.0 (CH₂), 71.9 (C-3), 116.9 (C-8), 117.5 (C-4a), 123.3 (C-6), 123.7 (C-5^A), 127.6 (C-5), 137.1 (C-7), 141.6 (C-8a), 147.4 (C-4^A), 168.7 (C-2), 190.8 (C-4); IR (cm⁻¹): ν 3148, 2992, 2919, 1729, 1682, 1613, 1486, 1378, 1345, 1235, 1189, 1009, 751, 667, 590; MS (EI) m/z (%): 273 (2, [M + 1]⁺), 272 (13, [M]⁺), 185 (68), 175 (89), 174 (45), 146 (100), 128 (58), 120 (70), 119 (75), 92 (66), 91 (39), 77 (39), 65 (37), 55 (39), 42 (79); HRMS (ESI+): m/z calcd for C₁₃H₁₃N₄O₃⁺ [M + H]⁺ 273.0982, found 273.0981. Anal. Calcd for C₁₃H₁₂N₄O₃ (272.26): C, 57.35; H, 4.44; N, 20.58%. Found: C, 57.20; H, 4.42; N, 20.83%.

3-(4-(Hydroxymethyl)-1H-1,2,3-triazol-1-yl)-3-phenylquinoline-2,4(1H,3H)-dione dimethylformamide solvate (1d·DMF). Colorless solid, m.p. 139–143 °C (ethanol); m.p. [9] 116–135 °C (benzene); $R_f = 0.27$ (10% ethanol in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 4.53 (d, 2H, J = 5.7 Hz, CH₂), 5.22 (t, 1H, J = 5.7 Hz, OH), 7.09 (d, 1H, J = 8.1 Hz, H-8), 7.13–7.18 (m, 1H, H-6), 7.36–7.42 (m, 2H, H-2^C, H-6^C), 7.47–7.53 (m, 3H, H-3^C, H-4^C, H-5^C), 7.59–7.65 (m, 1H, H-7), 7.77 (s, 1H, H-5^A), 7.83 (dd, 1H, J = 7.8, 1.3 Hz, H-5), 11.60 (s, 1H, H-1); ¹³C NMR (126 MHz, DMSO- d_6) δ 55.0 (CH₂), 79.7 (C-3), 116.7 (C-8), 119.2 (C-4a), 123.4 (C-6), 124.8 (C-5^A), 127.5 (C-5), 128.8 (C-2^C, C-6^C), 129.6 (C-3^C, C-5^C), 130.2 (C-1^C), 130.5 (C-4^C), 136.9 (C-7), 140.6 (C-8a), 146.8 (C-4^A), 166.8 (C-2), 189.0 (C-4); IR (cm⁻¹): ν 3392, 3136, 2926, 1724, 1692, 1654, 1613, 1485, 1438, 1353, 857, 769, 752, 665, 603; MS (EI) m/z (%): 335 (0.8, [M + 1]⁺), 334 (4, [M]⁺), 305 (37), 275 (18), 249 (30), 247 (27), 237 (50), 236 (100), 218 (35), 208 (18), 180 (20), 120 (33), 104 (23), 92 (23), 77 (34); HRMS (ESI+): m/z calcd for C₁₈H₁₅N₄O₃⁺ [M + H]⁺ 335.1139, found 335.1138. Anal. Calcd for C₂₁H₂₁N₅O₄ (407.42): C, 61.91; H, 5.20; N, 17.19%. Found: C, 61.89; H, 5.24; N, 17.28%.

3.5. Synthesis of Compound **1a** by Employing $CuSO_4 \cdot 5H_2O/L$ -Ascorbic Acid/CH₂Cl₂/Water Conditions (Table 2, Entry 2)

To a solution of azide **5a** (162 mg, 0.75 mmol) and phenylacetylene (**6a**) (153 mg, 1.5 mmol) in dichloromethane (8 mL) a solution of L-ascorbic acid (106 mg, 0.60 mmol) in water (4 mL), and a solution of $CuSO_4 \cdot 5H_2O$ (15 mg, 0.06 mmol) in water (4mL) were added. The two-phase reaction mixture was stirred in darkness at room temperature for 48 h. The reaction mixture was extracted with chloroform (5 × 30 mL). The combined organic layers were dried (Na₂SO₄), filtered, and evaporated to dryness. The residue was dissolved in chloroform (5 mL) and subjected to silica gel (30 g) column chromatography using 38% ethyl acetate in hexane as eluent, affording compound **1a** (199 mg, 63 mmol 83%).

3.6. General Procedure for the Synthesis of (1-(2,4-Dioxo-1,2,3,4-Tetrahydroquinolin-3-yl)-1H-1,2,3-Triazol-4-yl)Methyl Acetates 1e,f (Scheme 2)

Acetic anhydride (12 mL, 12.9 g, 126 mmol) was added to a light yellow solution of compound **1c** or **1d** (6 mmol) in pyridine (18 mL) under stirring during 2 min. The reaction mixture was stirred for 1 h, followed by evaporation of volatiles under reduced pressure. The remaining pyridine was removed by co-distillation with ethanol (6×40 mL). The residue was triturated with water (300 mL) to form a white precipitate which was collected by filtration on a sintered glass filter with suction, washed with water to neutral and dried to give acetates **1e** or **1f**. The crude product was recrystallized from the solvent indicated below.

(1-(3-Methyl-2,4-dioxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-1,2,3-triazol-4-yl)methyl acetate (1e). Compound 1e (1.58 g, 5.04 mmol, 84%) was prepared from 1c (1.63 g, 6.0 mmol). Pale yellow solid, m.p. 145–148 °C (ethyl acetate); $R_f = 0.33$ (5% ethanol in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.06 (s, 3H, COCH₃), 2.09 (s, 3H, C-3–CH₃), 5.16 (s, 2H, CH₂), 7.19–7.26 (m, 2H, H-6, H-8), 7.70–7.77 (m, 1H, H-7), 7.83 (dd, 1H, *J* = 8.0, 1.4 Hz, H-5), 8.45 (s, 1H, H-5^A), 11.40 (s, 1H, H-1); ¹³C NMR (126 MHz, DMSO- d_6) δ 20.6 (COCH₃), 23.2 (C-3–CH₃), 57.1 (CH₂), 72.4 (C-3), 116.9 (C-8), 117.5 (C-4a), 123.3 (C-6), 125.8 (C-5^A), 127.6 (C-5), 137.1 (C-7), 141.4 (C-4^A), 141.6 (C-8a), 168.6 (C-2), 170.1 (COCH₃), 190.7 (C-4); ¹⁵N NMR (51 MHz, DMSO- d_6) δ 133.5 (N-1), 248.7 (N-1^A), 354.1 (N-3^A), 362.9 (N-2^A); IR (cm⁻¹): ν 3467, 3249, 3148, 2920, 1722, 1685, 1613, 1485, 1439, 1384, 1355, 1239, 1028, 759, 666; MS (EI) *m/z* (%):

315 (2, $[M + 1]^+$), 314 (11, $[M]^+$), 244 (22), 201 (22), 175 (71), 174 (31), 146 (43), 128 (26), 120 (25), 119 (27), 92 (24), 55 (20), 43 (100), 42 (26); HRMS (ESI+): m/z calcd for $C_{15}H_{15}N_4O_4^+$ $[M + H]^+$ 315.1088, found 315.1087. Anal. Calcd for $C_{15}H_{14}N_4O_4$ (314.30): C, 57.32; H, 4.49; N, 17.83%. Found: C, 57.32; H, 4.59; N, 17.58%.

(1-(2,4-Dioxo-3-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-1,2,3-triazol-4-yl)methyl acetate (1f). Compound 1f (1.92 g, 5.1 mmol, 85%) was prepared from 1d (2.01 g, 6.0 mmol). Colorless crystals, m.p. 130–134 °C (ethanol, 80% yield of recrystallization); $R_f = 0.40$ (5% ethanol in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.04 (s, 3H, CH₃), 5.13 (s, 2H, CH₂), 7.09 (d, 1H, J = 8.1 Hz, H-8), 7.13–7.18 (m, 1H, H-6), 7.35–7.42 (m, 2H, H-2^C, H-6^C), 7.46–7.54 (m, 3H, H-3^C, H-4^C, H-5^C), 7.59–7.65 (m, 1H, H-7), 7.83 (dd, 1H, J = 7.8, 1.3 Hz), 8.07 (s, 1H, H-5^A), 11.62 (s, 1H, H-1); ¹³C NMR (126 MHz, DMSO- d_6) δ 20.7 (CH₃), 57.1 (CH₂), 79.9 (C-3), 116.7 (C-8), 119.3 (C-4a), 123.4 (C-6), 127.0 (C-5^A), 127.5 (C-5), 128.8 (C-2^C, C-6^C), 129.6 (C-3^C, C-5^C), 130.0 (C-1^C), 130.6 (C-4^C), 136.9 (C-7), 140.5 (C-8a), 140.8 (C-4^A), 166.8 (C-2), 170.1 (COCH₃), 188.8 (C-4); IR (cm–1): ν 3501, 3155, 2920, 1722, 1707, 1686, 1614, 1594, 1484, 1358, 1252, 1229, 1063, 857, 759; MS (EI) m/z (%): 377 (1, [M + 1]+), 376 (6, [M]+), 306 (16), 289 (18), 288 (54), 263 (15), 237 (50), 236 (100), 218 (34), 180 (14), 141 (14), 120 (24), 92 (14), 77 (19), 43 (16); HRMS (ESI+): m/z calcd for C₂₀H₁₇N₄O₄⁺ [M + H]⁺ 377.1244, found 377.1241.

3.7. General Procedure for the Synthesis of 3-(1H-1,2,3-Triazol-1-yl)-1-(prop-2-yn-1-yl)Quinoline-2,4(1H,3H)-Diones 7 (Table 3)

The mixture of the appropriate compound **1***a*,**b**,**e**,**f** (8.00 mmol), potassium carbonate (3.32 g, 24 mmol), and DMF (40 mL) was stirred for 40 min. During this time, the original yellow color of the suspension changed to orange. Afterwards, under continued stirring, an 80% solution of propargyl bromide (**6c**) in toluene (1.78 g, 12 mmol) diluted with DMF (20 mL) was added dropwise during 1 min and stirring was continued for 90 min. Then the mixture was reduced *in vacuo* and then toluene (50 mL) was added and the whole evaporated *in vacuo* at 50 °C. This was repeated seven times in order to remove traces of DMF. The residual light brown solid was suspended in chloroform (100 mL) and the suspension was acidified with 0.5 M HCl, whereas carbon dioxide was evolved owing to decomposition of unreacted potassium carbonate. The formed emulsion was diluted with water, organic phase was separated and aqueous phase was extracted with chloroform (5 × 40 mL). The organic phases were combined, dried (Na₂SO₄), filtered and taken down *in vacuo*. The residual solid TLC pure product was crystallized from a suitable solvent. The yields of prepared compounds 7 are given in Table 3.

3-Methyl-3-(4-phenyl-1*H***-1,2,3-triazol-1-yl)-1-(prop-2-yn-1-yl)quinoline-2,4(1***H***,3***H***)-dione (7a). Colorless crystals, m.p. 187–189 °C (benzene); R_f = 0.63 (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO-d_6) \delta 2.16 (s, 3H, CH₃), 3.39 (dd, 1H,** *J* **= 2.3, 2.3 Hz, C≡CH), 4.90 (dd, 1H,** *J* **= 18.1, 2.3 Hz, N-1–CH\alpha), 4.97 (dd, 1H,** *J* **= 18.1, 2.3 Hz, N-1–CH\beta), 7.34–7.42 (m, 2H, H-6, H-4^B), 7.48 (dd, 2H,** *J* **= 7.7, 7.7 Hz, H-3^B, H-5^B), 7.61 (d, 1H,** *J* **= 8.4 Hz, H-8), 7.84–7.89 (m, 2H, H-2^B, H-6^B), 7.89–7.95 (m, 1H, H-7), 8.00 (dd,** *J* **= 7.7, 1.5 Hz, H-5), 8.89 (s, 1H, H-5^A); ¹³C NMR (126 MHz, DMSO-d_6) \delta 2.3.3 (CH₃), 32.7 (N-1–CH₂), 72.6 (C-3), 75.4 (C≡CH), 78.2 (C≡CH), 116.7 (C-8), 119.0 (C-4a), 122.5 (C-5^A), 124.2 (C-6), 125.1 (C-2^B, C-6^B), 128.1 (C-4^B), 128.2 (C-5), 129.0 (C-3^B, C-5^B), 130.5 (C-1^B), 137.3 (C-7), 140.8 (C-8a), 145.9 (C-4^A), 167.7 (C-2), 189.7 (C-4); IR (cm⁻¹):** *v* **3261, 3173, 2122, 1713, 1678, 1601, 1469, 1427, 1381, 1368, 1353, 1306, 1189, 769, 754; MS (EI)** *m/z* **(%): 357 (2, [M + 1]⁺), 356 (8, [M]⁺), 259 (10), 128 (11), 117 (16), 116 (100), 102 (17), 90 (11), 89 (16), 77 (10), 76 (10); HRMS (ESI+):** *m/z* **calcd for C₂₁H₁₇N₄O₂⁺ [M + H]⁺ 357.1346, found 357.1342. Anal. Calcd for C₂₁H₁₆N₄O₂ (356.38): C, 70.77; H, 4.53; N, 15.72%. Found: C, 70.81; H, 4.58; N, 15.82%.**

3-Phenyl-3-(4-phenyl-1*H***-1,2,3-triazol-1-yl)-1-(prop-2-yn-1-yl)quinoline-2,4(1***H***,3***H***)-dione (7b). Colorless crystals, m.p. 232–234 °C (ethanol); R_f = 0.69 (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) \delta 2.34 (dd, 1H, J = 2.4, 2.4 Hz), 4.51 (dd, 1H, J = 17.8, 2.3 Hz), 5.37 (dd, 1H, J = 17.8, 2.3 Hz), 7.23 (dd, 1H, J = 7.6, 7.6 Hz), 7.26 (s, 1H), 7.27–7.31 (m, 1H), 7.32–7.40 (m, 3H), 7.43–7.51 (m, 3H), 7.51–7.56 (m, 2H), 7.62–7.69 (m, 1H), 7.73–7.81 (m, 2H), 8.05 (dd, 1H, J = 7.7, 1.4 Hz); ¹³C NMR** (126 MHz, CDCl₃) δ 33.6, 73.6, 76.9, 79.6, 115.8, 121.0, 122.3, 124.6, 126.0, 128.1, 128.8, 129.0, 129.2, 130.0, 130.1, 130.7, 131.3, 136.9, 140.6, 146.0, 165.8, 187.5; IR (cm⁻¹): ν 3197, 2983, 2118, 1716, 1680, 1603, 1468, 1448, 1304, 1039, 870, 760, 752, 694; MS (EI) m/z (%): 419 (13, [M + 1]⁺), 418 (75, [M]⁺), 390 (43), 287 (22), 286 (31), 285 (89), 276 (25), 275 (100), 274 (28), 259 (70), 248 (46), 235 (53), 145 (52), 116 (95), 44 (99); HRMS (ESI+): m/z calcd for C₂₆H₁₉N₄O₂⁺ [M + H]⁺ 419.1503, found 419.1502. Anal. Calcd for C₂₆H₁₈N₄O₂: C, 74.63; H, 4.34; N, 13.39%. Found: C, 74.45; H, 4.40; N, 13.43%.

(1-(3-Methyl-2,4-dioxo-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-1,2,3-triazol-4-yl)methyl acetate (7c). Colorless crystals, m.p. 159–161 °C (ethyl acetate); $R_f = 0.29$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.06 (s, 3H, COCH₃), 2.10 (s, 3H, C-3–CH₃), 3.37 (dd, 1H, J = 2.4, 2.4 Hz, C≡CH), 4.84 (dd, 1H, J = 18.1, 2.4 Hz, N-1–CH α), 4.95 (dd, 1H, J = 18.1, 2.4 Hz, N-1–CH β), 5.17 (s, 2H, OCH₂), 7.37 (dd, 1H, J = 7.5, 7.5 Hz, H-6), 7.58 (d, 1H, J = 8.4 Hz, H-8), 7.87–7.93 (m, 1H, H-7), 7.96 (dd, 1H, J = 7.7, 1.5 Hz, H-5), 8.46 (s, 1H, H-5^A); ¹³C NMR (126 MHz, DMSO- d_6) δ 20.6 (COCH₃), 23.4 (C-3–CH₃), 32.6 (N-1–CH₂), 57.1 (OCH₂), 72.8 (C-3), 75.3 (C≡CH), 78.2 (C≡CH), 116.6 (C-8), 119.2 (C-4a), 124.0 (C-6), 126.0 (C-5^A), 128.0 (C-5), 137.1 (C-7), 140.7 (C-8a), 141.5 (C-4^A), 167.8 (C-2), 170.1 (COCH₃), 189.63 (C-4); ¹⁵N NMR (51 MHz, DMSO- d_6) δ 134.4 (N1), 247.9 (N-1^A), 354.0 (N-3^A), 363.4 (N-2^A); IR (cm⁻¹): ν 3256, 3152, 2122, 1721, 1687, 1604, 1471, 1383, 1306, 1246, 1194, 1053, 1008, 756; MS (EI) *m*/*z* (%): 353 (3, [M + 1]⁺), 352 (12, [M]⁺), 213 (69), 212 (34), 184 (19), 156 (32), 146 (17), 130 (19), 129 (21), 128 (22), 77 (17), 57 (16), 55 (23), 43 (100), 42 (17); HRMS (ESI+): *m*/*z* calcd for C₁₈H₁₇N₄O₄⁺ ([M+H]⁺): 353.1244, found 353.1246. Anal. Calcd for C₁₈H₁₆N₄O₄ (352.34): C, 61.36; H, 4.58; N, 15.90%. Found: C, 61.27; H, 4.64; N, 15.87%.

(1-(2,4-Dioxo-3-phenyl-1-(prop-2-yn-1-yl)-1,2,3,4-tetrahydroquinolin-3-yl)-1H-1,2,3-triazol-4-yl)methyl acetate (7d). Colorless crystals, m.p. 210–214 °C; $R_f = 0.66$ (5% ethanol in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.05 (s, 3H, COCH₃), 3.41 (dd, 1H, J = 2.4, 2.3 Hz, C \equiv CH), 4.80 (dd, 1H, J = 18.0, 2.3 Hz, N-1–CH α), 5.09–5.20 (m, 3H, N-1–CH β , OCH₂), 7.24–7.32 (m, 3H, H-6, H-2^C, H-6^C), 7.41–7.51 (m, 4H, H-8, H-3^C, H-4^C, H-5^C), 7.73–7.79 (m, 1H, H-7), 7.92 (dd, 1H, J = 7.7, 1.5 Hz, H-5), 8.15 (s, 1H, H-5^A); ¹³C NMR (126 MHz, DMSO- d_6) δ 20.6 (COCH₃), 33.1 (N-1–CH₂), 57.1 (OCH₂), 75.5 (C \equiv CH), 77.9 (C \equiv CH), 80.0 (C-3), 116.3 (C-8), 120.9 (C-4a), 124.2 (C-6), 127.1 (C-5^A), 127.8 (C-5), 128.6 (C-2^C, C-6^C), 129.5 (C-3^C, C-5^C), 129.9 (C-1^C), 130.7 (C-4^C), 136.7 (C-7), 140.0 (C-8a), 140.9 (C-4^A), 165.8 (C-2), 170.1 (COCH₃), 187.7 (C-4); IR (cm⁻¹): ν 3227, 3152, 2116, 1736, 1715, 1683, 1602, 1467, 1379, 1303, 1251, 1036, 764, 747, 694; MS (EI) m/z (%): 415 (2, [M + 1]⁺), 414 (7, [M]⁺), 313 (26), 275 (72), 274 (63), 246 (28), 235 (31), 218 (29), 217 (30), 156 (26), 130 (29), 105 (22), 104 (29), 103 (22), 43 (100); HRMS (ESI+): m/z calcd for C₂₃H₁₉N₄O₄⁺ [M + H]⁺ 415.1401, found 415.1403. Anal. Calcd for C₂₃H₁₈N₄O₄: C, 66.66; H, 4.38; N, 13.52%.

3.8. General Procedure for the Synthesis of Bis-Triazoles 2a,b,d,e,g,h,j,k by Employing CuSO₄/Cu⁰/DMF Conditions (Table 4, Entries 1, 2, 4, 8, 10, 11, 13 and 14)

A solution of azidobenzene (**8b**, 197 mg, 1.65 mmol) or (azidomethyl)benzene (**8a**, 220 mg, 1.65 mmol) in DMF (4 mL) was added to a vigorously stirred mixture of the appropriate *N*-propargylquinoline-2,4(1*H*,3*H*)-dione 7 (1.5 mmol), CuSO₄·5H₂O (38 mg, 0.15 mmol) and granular copper (191 mg, 3.05 mmol) in DMF (5 mL). The reaction mixture was stirred in darkness at room temperature for the time given in Table 4. The color of the mixture became brown-black. Then, $(NH_4)_2CO_3$ (432 mg, 4.5 mmol) and water (2 mL) were added to the reaction mixture and the stirring was continued for 10 min. The reaction mixture was poured into a narrow (1 cm in diameter) column of silica gel (15 g). The organic portion was eluted with 10% ethanol in chloroform (approximately 150 mL). The yellow eluate was washed with saturated aqueous NH₄Cl (50 mL), dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation *in vacuo*. The TLC pure product thus prepared, with the exception of compounds **2d**,**e**,**k**, was crystallized from suitable solvent. The yields of prepared compounds **2** are given in Table **4**.

1-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-methyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline-2,4 (**1***H,3H*)-**dione (2a).** Colorless crystals, m.p. 202–204 °C (ethanol); $R_f = 0.40$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.18 (s, 3H, CH₃), 5.24 (d, 1H, *J* = 16.2 Hz, N-1–CH α), 5.49 (d, 1H, *J* = 16.2 Hz, N-1–CH β), 5.58 (s, 2H, N-1^D–CH₂), 7.24–7.29 (m, 2H, H-2^E, H-6^E), 7.29–7.40 (m, 5H, H-6, H-4^B, H-3^E, H-4^E, H-5^E), 7.49 (dd, 2H, *J* = 7.7, 7.7 Hz, H-3^B, H-5^B), 7.67 (d, 1H, *J* = 8.5 Hz, H-8), 7.79–7.90 (m, 3H, H-7, H-2^B, H-6^B), 7.96 (dd, 1H, *J* = 7.7, 1.4 Hz, H-5), 8.16 (s, 1H, H-5^D), 8.87 (s, 1H, H-5^A); ¹³C NMR (126 MHz, DMSO- d_6) δ 23.4 (CH₃), 38.7 (N-1–CH₂), 52.8 (N-1^D–CH₂), 72.8 (C-3), 116.7 (C-8), 119.1 (C-4a), 122.5 (C-5^A), 123.8 (C-5^D), 123.9 (C-6), 125.1 (C-2^B, C-6^B), 127.9 (C-2^E, C-6^E), 128.0 (C-4^B), 128.1 (C-5), 128.1 (C-4^E), 128.7 (C-3^E, C-5^E), 129.1 (C-3^B, C-5^B), 130.6 (C-1^B), 136.0 (C-1^E), 137.2 (C-7), 141.5 (C-8a), 142.2 (C-4^D), 145.9 (C-4^A), 168.2 (C-2), 190.0 (C-4); IR (cm⁻¹): *v* 3137, 3128, 1711, 1673, 1600, 1471, 1387, 1051, 768, 761, 718, 694; MS (EI) *m/z* (%): 490 (2, [M + 1]⁺), 489 (6, [M]⁺), 289 (13), 145 (17), 144 (16), 117 (11), 116 (44), 91 (100), 90 (10), 89 (12); HRMS (ESI+): *m/z* calcd for C₂₈H₂₄N₇O₂⁺ [M + H]⁺ 490.1986, found 490.1981. Anal. Calcd for C₂₈H₂₃N₇O₂ (489.53) C, 68.70; H, 4.74; N, 20.03. Found: C, 68.71; H, 4.78; N, 20.36.

3-Methyl-3-(4-phenyl-1*H***-1,2,3-triazol-1-yl)-1-((1-phenyl-1***H***-1,2,3-triazol-4-yl)methyl)quinoline-2,4 (1***H,3H***)-dione (2b). Colorless crystals, m.p. 194–197 °C (benzene); R_f = 0.48 (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO-d_6) \delta 2.23 (s, 3H, CH₃), 5.33 (d, 1H,** *J* **= 16.4 Hz, N-1–CH\alpha), 5.62 (d, 1H,** *J* **= 16.4 Hz, N-1–CH\beta), 7.31–7.39 (m, 2H, H-6, H-4^B), 7.45–7.52 (m, 3H, H-3^B, H-5^B, H-4^E), 7.55–7.62 (m, 2H, H-3^E, H-5^E), 7.70 (d, 1H,** *J* **= 8.5 Hz, H-8), 7.82–7.91 (m, 5H, H-7, H-2^B, H-6^B, H-2^E, H-6^E), 7.98 (dd, 1H,** *J* **= 7.7, 1.5 Hz, H-5), 8.75 (s, 1H, H-5^D), 8.87 (s, 1H, H-5^A); ¹³C NMR (126 MHz, DMSO-d_6) \delta 23.4 (CH₃), 38.7 (N-1–CH₂), 73.0 (C-3), 116.8 (C-8), 119.2 (C-4a), 120.2 (C-2^E, C-6^E), 121.8 (C-5^D), 122.5 (C-5^A), 124.0 (C-6), 125.2 (C-2^B, C-6^B), 128.1 (C-4^B), 128.1 (C-5), 128.8 (C-4^E), 129.1 (C-3^B, C-5^B), 129.9 (C-3^E, C-5^E), 130.6 (C-1^B), 136.5 (C-1^E), 137.3 (C-7), 141.6 (C-8a), 143.3 (C-4^D), 146.0 (C-4^A), 168.3 (C-2), 190.0 (C-4); ¹⁵N NMR (51 MHz, DMSO-d_6) \delta 136.3 (N1), 248.9 (N-1^A), 255.7 (N-D-1), 347.1 (N-3^A), 353.4 (N-3^D), 358.1 (N-2^D), 363.2 (N-2^A); IR (cm⁻¹): \nu 3275, 1721, 1690, 1613, 1485, 1353, 854, 771, 756, 698, 666, 607, 520; MS (EI) m/z (%): 476 (3, [M + 1]⁺), 475 (8, [M]⁺), 289 (14), 145 (12), 131 (11), 130 (100), 129 (18), 128 (11), 116 (56), 104 (12), 103 (16), 102 (12), 89 (12), 77 (69); HRMS (ESI+): m/z calcd for C₂₇H₂₂N₇O₂⁺ [M + H]⁺ 476.1829, found 476.1825. Anal. Calcd for C₂₇H₂₁N₇O₂ (475.50): C, 68.20; H, 4.45; N, 20.62%. Found: C, 68.48; H, 4.53; N, 20.60%.**

(1-(1-(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-1,2,3-triazol-4-yl)methyl acetate (2d). Colorless powder, m.p. 69–82 °C; $R_f = 0.42$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃), δ 2.09 (s, 3H, COCH₃), 2.12 (s, 3H, C-3–CH₃), 5.25 (s, 2H, OCH₂), 5.33 (s, 2H, N-1-CH₂), 5.45 (d, 1H, *J* = 14.8 Hz, N-1^D–CH α), 5.51 (d, 1H, *J* = 14.8 Hz, N-1^D–CH β), 7.23–7.26 (m, 3H, H-6, H-2^E, H-6^E), 7.32–7.38 (m, 3H, H-3^E, H-4^E, H-5^E), 7.55 (s, 1H, H-5^D), 7.73 (ddd, 1H, *J* = 8.7, 7.1, 1.6 Hz, H-7), 7.78 (s, 1H, H-5^A), 7.82 (d, 1H, *J* = 8.4 Hz, H-8), 8.02 (dd, 1H, *J* = 7.7, 1.6 Hz, H-5); ¹³C NMR (126 MHz, CDCl₃) δ 21.1 (COCH₃), 23.5 (C-3–CH₃), 39.5 (N-1–CH₂), 54.5 (N-1^D–CH₂), 57.7 (OCH₂), 71.6 (C-3), 116.9 (C-8), 119.2 (C-4a), 123.5 (C-5^D), 124.2 (C-5^A), 124.6 (C-6), 128.3 (C-2^E, C-6^E), 129.0 (C-4^E), 129.3 (C-3^E, C-5^E), 129.3 (C-5), 134.4 (C-1^E), 137.8 (C-7), 141.7 (C-8a), 142.3 (C-4^A), 142.9 (C-4^D), 168.2 (C-2), 171.1 (COCH₃), 189.4 (C-4); ¹⁵N NMR (51 MHz, CDCl₃) δ 138.7 (N-1), 248.4 (N-1^A), 250.4 (N-1^D), 350.0 (N-3^D), 355.2 (N-3^A), 361.6 (N-2^A), 362.6 (N-2^D); IR (cm⁻¹): *v* 3143, 2930, 1739, 1717, 1679, 1602, 1470, 1384, 1243, 1186, 1050, 1028, 765, 721, 664; MS (EI) *m/z* (%): 486 (0.3, [M + 1]⁺), 485 (1, [M]⁺), 144 (18), 91 (100), 43 (24); HRMS (ESI+): *m/z* calcd for C₂₅H₂₄N₇O₄⁺ [M + H]⁺ 486.1884, found 486.1884.

(1-(3-Methyl-2,4-dioxo-1-((1-phenyl-1*H*-1,2,3-triazol-4-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-1,2,3-triazol-4-yl)methyl acetate (2e). Colorless powder, m.p. 78–97 °C; $R_f = 0.25$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 2.10 (s, 3H, COCH₃), 2.20 (s, 3H, C-3–CH₃), 5.27 (s, 2H, OCH₂), 5.42 (d, 1H, *J* = 15.8 Hz, N-1–CH α), 5.52 (d, 1H, *J* = 15.8 Hz, N-1–CH β), 7.27–7.30 (m, 1H, H-6), 7.41–7.47 (m, 1H, H-4^E), 7.49–7.55 (m, 2H, H-3^E, H-5^E), 7.69–7.74 (m, 2H, H-2^E, H-6^E), 7.76 (ddd, 1H, *J* = 8.1, 7.7, 1.6 Hz, H-7), 7.85 (d, 1H, *J* = 7.3 Hz, H-8), 7.86 (s, 1H, H-5^A), 8.05 (dd, 1H, *J* = 7.8, 1.5 Hz, N-1–CH α).

15 of 21

H-5), 8.10 (s, 1H, H-5^D); ¹³C NMR (126 MHz, CDCl₃) δ 21.0 (COCH₃), 23.4 (C-3–CH₃), 39.5 (N-1-CH₂), 57.7 (OCH₂), 71.5 (C-3), 116.8 (C-8), 119.2 (C-4a), 120.6 (C-2^E, C-6^E), 121.7 (C-5^D), 124.1 (C-5^A), 124.7 (C-6), 129.1 (C-4^E), 129.4 (C-5), 129.9 (C-3^E, C-5^E), 136.9 (C-1^E), 137.8 (C-7), 141.7 (C-8a), 142.3 (C-4^A), 143.2 (C-4^D), 168.3 (C-2), 171.1 (COCH₃), 189.4 (C-4); ¹⁵N NMR (51 MHz, CDCl₃) δ 138.7 (N-1), 248.8 (N-1^A), 256.3 (N-1^D), 351.9 (N-3^D), 355.5 (N-3^A); IR (cm⁻¹): ν 3145, 2926, 1740, 1717, 1681, 1601, 1470, 1384, 1242, 1184, 1046, 761, 691, 664; MS (EI) m/z (%): 472 (0.9, [M + 1]⁺), 471 (3, [M]⁺), 303 (20), 302 (17), 131 (13), 130 (100), 129 (14), 77 (44), 43 (25); HRMS (ESI+): m/z calcd for C₂₄H₂₂N₇O₄⁺ [M + H]⁺ 472.1728, found 472.1726.

1-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)-3-phenyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline-2,4 (**1H,3H)-dione (2g).** Colorless crystals, m.p. 142–145 °C (ethanol); $R_f = 0.42$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 5.15 (d, 1H, J = 15.8 Hz, N-1–CH α), 5.62 (s, 2H, N-1^D–CH₂), 5.63 (d, 1H, J = 15.8 Hz, N-1–CH β), 7.22–7.50 (m, 14H, H-6, H-3^B, H-4^B, H-5^B, H-2^C, H-3^C, H-4^C, H-5^C, H-6^C, H-2^E, H-3^E, H-4^E, H-5^E, H-6^E), 7.68 (d, 1H, J = 7.8 Hz, H-8), 7.73 (ddd, 1H, J = 8.5, 7.1, 1.7 Hz, H-7), 7.80–7.83 (m, 2H, H-2^B, H-6^B), 7.92 (dd, 1H, J = 7.7, 1.5 Hz, H-5), 8.24 (s, 1H, H-5^D), 8.51 (s, 1H, H-5^A); ¹³C NMR (126 MHz, DMSO- d_6) δ 39.2 (N-1–CH₂), 52.8 (N-1^D–CH₂), 80.1 (C-3), 116.7 (C-8), 120.9 (C-4a), 123.4 (C-5^A), 124.0 (C-6), 124.2 (C-5^D), 125.2 (C-2^B, C-6^B), 127.9 (C-5), 128.0 (C-4^C, C-2^E, C-6^E), 128.2 (C-4^B), 128.7 (C-1^C), 128.8 (C-3^E, C-5^E), 129.0 (C-3^B, C-5^B), 129.4 (C-2^C, C-6^C), 129.8 (C-1^B), 130.5 (C-3^C, C-5^C, C-4^E), 136.0 (C-1^E), 136.8 (C-7), 140.8 (C-8a), 141.9 (C-4^D), 145.4 (C-4^A), 166.2 (C-2), 188.2 (C-4); IR (cm⁻¹): ν 3434, 3138, 3062, 1716, 1678, 1601, 1468, 1375, 1307, 1035, 870, 761, 724, 695; MS (EI) m/z (%): 552 (1, [M + 1]⁺), 551 (3, [M]⁺), 289 (23), 236 (11), 145 (18), 144 (17), 116 (31), 104 (10), 91 (100), 89 (11), 77 (16); HRMS (ESI+): m/z calcd for C₃₃H₂₆N₇O₂⁺ [M + H]⁺ 552.2142, found 552.2133. Anal. Calcd for C₃₃H₂₅N₇O₂ (551.60): C, 71.86; H, 4.57; N, 17.78%. Found: C, 71.58; H, 4.58; N, 17.73%.

3-Phenyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)quinoline-2,4 (1*H*,3*H*)-dione (2h). Colorless crystals, m.p. 152–157 °C (ethanol); $R_f = 0.54$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 5.33 (d, 1H, I = 16.1 Hz, N-1–CH α), 5.71 (d, 1H, I = 16.1Hz, N-1–CHβ), 7.25–7.29 (m, 1H, H-6), 7.32–7.48 (m, 8H, H-3^B, H-4^B, H-5^B, H-2^C, H-3^C, H-4^C, H-5^C, H-6^C), 7.48–7.53 (m, 1H, H-4^E), 7.58–7.64 (m, 2H, H-3^E, H-5^E), 7.70 (d, 1H, J = 8.2 Hz, H-8), 7.72–7.77 (m, 1H, H-7), 7.81–7.85 (m, 2H, H-2^B, H-6^B), 7.88–7.93 (m, 2H, H-2^E, H-6^E), 7.95 (dd, 1H, J = 7.7, 1.5 Hz, H-5), 8.54 (s, 1H, H-5^A), 8.83 (s, 1H, H-5^D); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 39.0 (N-1–CH₂), 80.3 (C-3), 116.7 (C-8), 120.2 (C-2^E, C-6^E), 120.9 (C-4a), 122.3 (C-5^D), 123.5 (C-5^A), 124.1 (C-6), 125.2 (C-2^B, C-6^B), 127.9 (C-5), 128.0 (C-4^B), 128.9 (C-4^E), 128.9 (C-2^C, C-6^C), 129.0 (C-3^B, C-3^B), 129.4 (C-3^C, C-5^C), 129.9 (C-1^C), 130.0 (C-3^E, C-5^E), 130.5 (C-4^C), 130.6 (C-1^B), 136.5 (C-1^E), 136.8 (C-7), 140.7 (C-8a), 142.9 (C-4^D), 145.4 (C-4^A), 166.4 (C-2), 188.2 (C-4); IR (cm⁻¹): v 3447, 3142, 3060, 1716, 1679, 1600, 1468, 1449, 1375, 1305, 1040, 871, 758, 693; MS (EI) *m*/*z* (%): 538 (1, [M + 1]⁺), 537 (3, [M]⁺), 366 (14), 262 (10), 236 (17), 145 (29), 131 (10), 130 (100), 129 (19), 128 (11), 118 (10), 116 (38), 104 (14), 103 (17), 102 (13), 90 (12), 89 (15), 77 (71), 51 (12); HRMS (ESI+): *m*/*z* calcd for C₃₂H₂₄N₇O₂⁺ ([M+H]⁺) 538.1986, found 538.1976. Anal. Calcd for Anal. calcd for C₃₂H₂₃N₇O₂ (537.57) C, 71.50; H, 4.31; N, 18.24%. Found: C, 71.22; H, 4.32; N, 17.94%.

(1-(1-((1-Benzyl-1*H*-1,2,3-triazol-4-yl)methyl)-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-1,2,3-triazol-4-yl)methyl acetate (2j). Colorless powder, m.p. 188–194 °C (ethanol); $R_f = 0.41$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 2.04 (s, 3H, CH₃), 5.17 (s, 2H, OCH₂), 5.21 (d, 1H, J = 15.6 Hz, N-1–CH α), 5.43 (d, 1H, J = 14.8 Hz, N-1^D–CH α), 5.51 (d, 1H, J = 15.6 Hz, N-1–CH α), 5.55 (d, 1H, J = 14.8 Hz, N-1^D–CH β), 7.08 (s, 1H, H-5^A), 7.18 (ddd, 1H, J = 7.5, 7.5, 0.8 Hz, H-6), 7.23–7.29 (m, 4H, H-3^C, H-5^C, H-2^E, H-6^E), 7.29–7.33 (m, 2H, H-2^C, H-6^C), 7.34–7.39 (m, 3H, H-3^E, H-4^E, H-5^E), 7.38–7.44 (m, 1H, H-4^C), 7.58 (s, 1H, H-5^D), 7.63 (ddd, 1H, J = 8.4, 7.4, 1.7 Hz, H-7), 7.75 (d, 1H, J = 8.3 Hz, H-8), 7.99 (dd, 1H, J = 7.7, 1.7 Hz, H-5); ¹³C NMR (126 MHz, CDCl₃) δ 21.0 (CH₃), 39.9 (N-1–CH₂), 54.5 (N-1^D–CH₂), 57.6 (OCH₂), 79.6 (C-3), 116.8 (C-8), 120.9 (C-4a), 123.5 (C-5^D), 124.6 (C-6), 126.4 (C-5^A), 128.3 (C-2^E, C-6^E), 128.7 (C-2^C, C-6^C), 129.0 (C-5), 129.1 (C-4^E), 129.4 (C-3^E, C-5^E), 129.7 (C-1^C), 130.0 (C-3^C, C-5^C), 131.3 (C-4^C), 134.5 (C-1^E), 137.2 (C-7), 140.9 (C-4^A), 141.1 (C-8a), 142.9 (C-4^D), 166.6 (C-2), 171.0 (COCH₃), 187.9 (C-4); ¹⁵N NMR (51 MHz, CDCl₃) δ 140.4 (N-1), 249.8 (N-1^A), 250.4 (N-1^D), 350.5 (N-3^D), 356.9 (N-3^A), 362.9 (N-2^D), 365.1 (N-2^A); IR (cm⁻¹): ν 3142, 2927, 1740, 1717, 1679, 1602, 1469, 1377, 1244, 768, 749, 714, 697; MS (EI) m/z (%): 548 (0.1, [M + 1]⁺), 547 (0.3, [M]⁺), 347 (13), 289 (13), 144 (14), 105 (10), 104 (13), 91 (100), 43 (29); HRMS (ESI+): m/z calcd for C₃₀H₂₆N₇O₄⁺ [M + H]⁺ 548.2041, found 548.2032.

(1-(2,4-Dioxo-3-phenyl-1-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)-1H-1,2,3-triazol-4-yl)methyl acetate (2k). Colorless powder, m.p. 93–105 °C; $R_f = 0.42$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 2.05 (s, 3H, CH₃), 5.19 (s, 2H, OCH₂), 5.42 (d, 1H, J = 15.7 Hz, N-1–CHα), 5.55 (d, 1H, J = 15.7 Hz, N-1–CHβ), 7.14 (s, 1H, H-5^A), 7.20 (ddd, 1H, J = 7.6, 7.6, 0.8 Hz, H-6), 7.38–7.49 (m, 6H, H-2^C, H-3^C, H-4^C, H-5^C, H-6^C, H-4^E), 7.49–7.55 (m, 2H, H-3^E, H-5^E), 7.66 (ddd, 1H, J = 8.5, 7.3, 1.7 Hz, H-7), 7.68–7.72 (m, 2H, H-2^E, H-6^E), 7.76 (d, 1H, J = 8.4 Hz, H-8), 8.03 (dd, 1H, J = 7.8, 1.5 Hz, H-5), 8.05 (s, 1H, H-5^D); ¹³C NMR (126 MHz, CDCl₃) δ 21.0 (CH₃), 39.8 (N-1-CH₂), 57.6 (OCH₂), 79.6 (C-3), 116.7 (C-8), 120.7 (C-2^E, C-6^E), 120.9 (C-4a), 121.8 (C-5^D), 124.7 (C-6), 126.4 (C-5^A), 128.9 (C-2^C, C-6^C), 129.1 (C-5), 129.2 (C-4^E), 129.9 (C-1^C), 130.0 (C-3^E, C-5^E), 130.2 (C-3^C, C-5^C), 131.4 (C-4^C), 136.9 (C-1^E), 137.4 (C-7), 140.9 (C-4^A), 140.9 (C-8a), 143.2 (C-4^D), 166.9 (C-2), 171.0 (COCH₃), 187.9 (C-4); ¹⁵N NMR (51 MHz, CDCl₃) δ 140.4 (N-1), 249.9 (N-1^A), 256.3 (N-1^D), 352.9 (N-3^D), 357.2 (N-3^A); IR (cm⁻¹): ν 3146, 2962, 1741, 1718, 1681, 1600, 1468, 1376, 1243, 1043, 762, 693, 665, 608; MS (EI) m/z (%): 534 (0.2, [M + 1]⁺), 533 (0.6, [M]⁺), 366 (12), 365 (11), 262 (12), 131 (11), 130 (100), 129 (19), 128 (12), 104 (14), 103 (16), 99 (18), 77 (62), 44 (17), 43 (52); HRMS (ESI+): m/z calcd for C₂₉H₂₄N₇O₄⁺ [M + H]⁺ 534.1884, found 534.1882.

3.9. General Procedure for the Synthesis of Bis-Triazoles $2c_if_ill$ by Employing $CuSO_4/Cu^0/DMF$ Conditions (Table 4, Entries 3, 9, 12 and 15)

A mixture of the appropriate *N*-propargylquinoline-2,4(1*H*,3*H*)-dione 7 (1.5 mmol), tetrazolo[1,5-*a*]pyridine (189 mg, 1.58 mmol), CuSO₄·5H₂O (38 mg, 0.15 mmol), granular copper (191 mg, 3.05 mmol) and DMF (9 mL) was heated in darkness to 95–105 °C (oil bath) for the time given in Table 4, whereas the color of the mixture changed from brown-black to dark green. The mixture was then allowed to cool to room temperature. Subsequently, $(NH_4)_2CO_3$ (432 mg, 4.5 mmol) and water (2 mL) were added and after stirring for 15 min, the mixture was poured into a narrow (1 cm diameter) column of silica gel (15 g). The organic portion was eluted from the column with 10% ethanol in chloroform. The yellow eluate was washed with saturated aqueous NH_4Cl (50 mL), dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation *in vacuo*. In the cases of **2c**,**i**, the residue, which was TLC pure compound, was crystallized from suitable solvent. In the cases of **2f**,**1**, the residue was purified by chromatography on silica gel column using chloroform as eluent. The yields of prepared compounds **2** are given in Table 4.

3-Methyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)quinoline-2,4(1H,3H)-dione (2c). Colorless crystals, m.p. 188–191 °C (benzene); $R_f = 0.29$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 2.23 (s, 3H, CH₃), 5.42 (d, 1H, J = 16.5 Hz, N-1–CH α), 5.58 (d, 1H, J = 16.5 Hz, N-1–CH β), 7.28–7.40 (m, 2H, H-6, H-4^B), 7.43–7.51 (m, 2H, H-3^B, H-5^B), 7.51–7.57 (m, 1H, H-5^E), 7.64 (d, 1H, J = 8.4 Hz, H-8), 7.78–7.90 (m, 3H, H-7, H-2^B, H-6^B), 7.99 (d, 1H, J = 7.5 Hz, H-5), 8.07–8.17 (m, 2H, H-3^E, H-4^E), 8.54–8.61 (m, 1H, H-6^E), 8.82 (s, 1H, H-5^D), 8.87 (s, 1H, H-5^A); ¹³C NMR (126 MHz, DMSO- d_6) δ 23.4 (CH₃), 38.7 (N-1–CH₂), 73.0 (C-3), 113.7 (C-3^E), 116.6 (C-8), 119.3 (C-4a), 120.6 (C-5^D), 122.5 (C-5^A), 123.9 (C-6), 124.5 (C-5^E), 125.2 (C-2^B, C-6^B), 128.1 (C-4^B), 128.1 (C-5), 129.1 (C-3^B, C-5^B), 130.5 (C-1^B), 137.2 (C-7), 140.3 (C-4^E), 141.4 (C-8a), 143.2 (C-4^D), 146.0 (C-4^A), 148.4 (C-2^E), 149.0 (C-6^E), 168.5 (C-2), 189.9 (C-4); ¹⁵N NMR (51 MHz, DMSO- d_6) δ 135.8 (N-1), 248.9 (N-1^A), 260.5 (N-1^D), 284.9 (N-1^E), 347.1 (N-3^A), 356.9 (N-3^D), 358.6 (N-2^D), 363.4 (N-2^A); IR (cm⁻¹): ν 3426, 3126, 2972, 1706, 1674, 1601, 1471, 1378, 1310, 1232, 1041, 777, 764; MS (EI) m/z (%): 477 (2, [M + 1]⁺), 476 (7, [M]⁺), 289 (11), 145 (14), 132 (14), 131 (96), 116 (50), 102 (10), 90 (10), 89 (13), 79 (20), 78 (100), 77 (10), 51 (10); HRMS (ESI+): m/z calcd for C₂₆H₂₁N₈O₂⁺ [M + H]⁺ 477.1782, found 477.1773. Anal. Calcd for C₂₆H₂₀N₈O₂ (476.48) C, 65.54; H, 4.23; N, 23.52%. Found: C, 65.68; H, 4.21; N, 23.63%.

(1-(3-Methyl-2,4-dioxo-1-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-1,2,3,4-tetrahydroquinolin-**3-yl)-1H-1,2,3-triazol-4-yl)methyl acetate (2f).** Colorless powder, m.p. 69–82 °C; *R*_f = 0.29 (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO-*d*₆) δ 2.06 (s, 3H, COCH₃), 2.18 (s, 3H, C3–CH₃), $5.17 (d, 1H, J = 12.7 Hz, O-CH\alpha), 5.20 (d, 1H, J = 12.7 Hz, O-CH\beta), 5.41 (d, 1H, J = 16.5 Hz, N-1-CH\alpha),$ 5.53 (d, 1H, J = 16.5 Hz, N-1–CH β), 7.31 (dd, 1H, J = 7.4, 7.4 Hz, H-6), 7.54 (dd, 1H, J = 8.8, 4.5 Hz, H-5^E), 7.59 (d, 1H, J = 8.5 Hz, H-8), 7.77–7.83 (m, 1H, H-7), 7.96 (dd, 1H, J = 7.7 Hz, J = 1.6 Hz, H-5), 8.08–8.14 (m, 2H, H-3^E, H-4^E), 8.47 (s, 1H, H-5^A), 8.55–8.59 (m, 1H, H-6^E), 8.82 (s, 1H, H-5^D); ¹³C NMR (126 MHz, DMSO-d₆) δ 20.6 (COCH₃), 23.5 (C3–CH₃), 38.7 (N-1–CH₂), 57.2 (OCH₂), 73.3 (C-3), 113.7 $(C-3^{E}), 116.5 \ (C-8), 119.4 \ (C-4a), 120.6 \ (C-5^{D}), 123.8 \ (C-6), 124.4 \ (C-5^{E}), 126.1 \ (C-5^{A}), 127.9 \ (C-5), 137.0 \ (C-5), 127.9 \ (C-5), 127.0 \ (C$ (C-7), 140.2 (C-4^E), 141.3 (C-8a), 141.6 (C-4^A), 143.2 (C-4^D), 148.3 (C-2^E), 148.9 (C-6^E), 168.6 (C-2), 170.1 (COCH₃), 189.9 (C-4); ¹⁵N NMR (51 MHz, DMSO-*d*₆) δ 135.3 (N1), 247.6 (N-1^A), 260.0 (N-1^D), 284.7 (N-1^E), 353.4 (N-3^A), 356.5 (N-3^D), 361.9 (N-2^D), 363.7 (N-2^A); IR (cm⁻¹): v 3152, 1741, 1718 1681, 1600, 1471, 1384, 1314, 1242, 1183, 1038, 782, 756, 663; MS (EI) *m*/*z* (%): 473 (0.7, [M + 1]⁺), 472 (2, [M]⁺), 304 (27), 303 (26), 302 (17), 132 (13), 131 (100), 79 (22), 78 (100), 43 (21); HRMS (ESI+): *m*/*z* calcd for $C_{23}H_{21}N_8O_4^+$ [M + H]⁺ 473.1680, found 473.1684. Anal. Calcd for $C_{23}H_{20}N_8O_4^{-1}H_2O$ (472.46): C, 57.38; H, 4.40; N, 23.27%. Found: C, 57.39; H, 4.36; N, 23.47%.

3-Phenyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)quinoline-2,4(1H,3H)-dione (2i). Colorless crystals, m.p. 188–192 °C (benzene); $R_f = 0.50$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, DMSO- d_6) δ 5.44 (d, 1H, J = 16.3 Hz, N-1–CH α), 5.67 (d, 1H, $I = 16.3 \text{ Hz}, \text{ N-1-CH}\beta$, 7.26 (dd, 1H, I = 7.5, 7.5 Hz, H-6), 7.32–7.40 (m, 3H, H-4^B, H-2^C, H-6^C), 7.41–7.52 (m, 5H, H-3^B, H-5^B, H-3^C, H-4^C, H-5^C), 7.52–7.61 (m, 2H, H-8, H-5^E), 7.68–7.75 (m, 1H, H-7), 7.78–7.86 (m, 2H, H-2^B, H-6^B), 7.96 (dd, 1H, J = 7.7, 1.5 Hz, H-5), 8.09–8.16 (m, 2H, H-3^E, H-4^E), 8.58 (s, 1H, H-5^A), 8.60 (ddd, 1H, J = 4.8, 1.3, 1.3 Hz, H-6^E), 8.81 (s, 1H, H-5^D); ¹³C NMR (126 MHz, DMSO- d_6) δ 39.1 (N-1-CH₂), 80.4 (C-3), 113.7 (C-3^E), 116.5 (C-8), 120.8 (C-5^D), 120.9 (C-4a), 123.4 (C-5^A), 124.0 (C-6), 124.5 (C-5^E), 125.2 (C-2^B, C-6^B), 127.9 (C-5), 128.0 (C-4^B), 128.9 (C-2^C, C-6^C), 129.0 (C-3^B, C-5^B), 129.4 (C-3^C, C-5^C), 130.0 (C-1^C), 130.5 (C-4^C), 130.6 (C-1^B), 136.8 (C-7), 140.2 (C-4^E), 140.5 (C-8a), 143.0 (C-4^D), 145.4 (C-4^A), 148.3 (C-2^E), 149.0 (C-6^E), 166.6 (C-2), 188.1 (C-4); ¹⁵N NMR (51 MHz, DMSO-*d*₆) δ 137.5 (N1), 248.7 (N-1^A), 260.4 (N-1^D), 284.8 (N-1^E), 347.2 (N-3^A), 357.7 (N-3^D), 367.4 (N-2^A); IR (cm⁻¹): ν 3418, 2973, 1718, 1679, 1596, 1477, 1467, 1450, 1049, 1031, 773, 766, 757, 701; MS (EI) *m/z* (%): 539 (1, [M + 1]⁺), 538 (3, [M]⁺), 236 (11), 145 (16), 132 (14), 131 (100), 116 (32), 91 (11), 89 (11), 79 (15), 78 (85), 77 (13); HRMS (ESI+): m/z calcd for $C_{31}H_{23}N_8O_2^+$ [M + H]⁺ 539.1938, found 539.1932. Anal. calcd for C₃₁H₂₂N₈O₂ (538.19): C, 69.13; H, 4.12; N, 20.81%. Found: C, 68.91; H, 4.17; N, 20.66%.

(1-(2,4-Dioxo-3-phenyl-1-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-1,2,3,4-tetrahydroquinolin-3-yl)-1H-1,2,3-triazol-4-yl)methyl acetate (2l). Colorless powder, m.p. 93–102 °C; $R_f = 0.18$ (30% ethyl acetate in chloroform); ¹H NMR (500 MHz, CDCl₃) δ 2.05 (s, 3H, COCH₃), 5.19 (s, 2H, OCH₂), 5.30 (d, 1H, *J* = 15.8 Hz, N-1-CHα), 5.71 (d, 1H, *J* = 15.8 Hz, N-1-CHβ), 7.13 (s, 1H, H-5^A), 7.19 (dd, 1H, *J* = 7.5, 7.5 Hz, H-6), 7.36 (dd, 1H, *J* = 7.3, 4.9 Hz, H-5^E), 7.38–7.42 (m, 2H, H-3^C, H-5^C), 7.42–7.48 (m, 3H, H-2^C, H-4^C, H-6^C), 7.63 (ddd, 1H, *J* = 8.3, 7.4, 1.6 Hz, H-7), 7.70 (d, 1H, *J* = 8.4 Hz, H-8), 7.88–7.95 (m, 1H, H-4^E), 8.02 (dd, 1H, *J* = 7.8, 1.5 Hz, H-5), 8.15 (d, 1H, *J* = 8.2 Hz, H-3^E), 8.47–8.53 (m, 1H, H-6^E), 8.63 (s, 1H, H-5^D); ¹³C NMR (126 MHz, CDCl₃) δ 21.0 (COCH₃), 39.9 (N-1–CH₂), 57.6 (OCH₂), 79.7 (C-3), 113.9 (C-3^E), 116.6 (C-8), 121.0 (C-4a), 121.0 (C-5^D), 124.0 (C-5^E), 124.6 (C-6), 126.4 (C-5^A), 128.9 (C-2^C, C-6^C), 129.1 (C-5), 129.7 (C-1^C), 130.2 (C-3^C, C-5^C), 131.3 (C-4^C), 137.2 (C-7), 139.3 (C-4^E), 140.9 (C-4^A), 141.2 (C-8a), 143.0 (C-4^D), 148.9 (C-6^E), 149.0 (C-2^E), 166.6 (C-2), 171.0 (COCH₃), 357.1 (N-3^A); IR (cm⁻¹): *v* 3155, 2926, 1741, 1718, 1682, 1599, 1470, 1375, 1313, 1243, 1034, 779, 697, 665; MS (EI) *m/z* (%): 535 (0.4, [M + 1]⁺), 534 (0.7, [M]⁺), 132 (14), 131 (100), 79 (19), 78 (93), 44 (11), 43 (31); HRMS (ESI+): *m/z* calcd for C₂₈H₂₃N₈O₄⁺ [M + H]⁺ 535.1837, found 535.1846.

3.10. Synthesis of Bis-Triazole 2d by Employing $CH_2Cl_2/Water/CuSO_4 \cdot 5H_2O/Na$ -Ascorbate Conditions (Table 4, Entry 5)

To a solution of acetylene **7c** (132 mg, 0.375 mmol) and azide **8a** (52.4 mg, 0.394 mmol) in dichloromethane (6.5 mL) a solution of sodium ascorbate (59.5 mg, 0.3 mmol) in water (5.5 mL), and a solution of $CuSO_4 \cdot 5H_2O$ (7.5 mg, 0.03 mmol) in water (1 mL) were added. The two-phase liquid reaction mixture was stirred in darkness at room temperature until the compound **7c** reacted completely according to TLC analysis (4 h). The reaction mixture was diluted with water (50 mL) and extracted with chloroform (4 × 30 mL). The combined organic layers were dried (Na₂SO₄), filtered, and evaporated to dryness. The residue was dissolved in chloroform (5 mL) and subjected to silica gel (25 g) column chromatography using 67% ethyl acetate in petroleum ether as eluent, affording product **2d** (155 mg, 0.32 mmol, 85%).

3.11. Synthesis of Bis-Triazole 2d by Employing t-BuOH/Water/CH₃CN/CuSO₄·5H₂O/Na-Ascorbate Conditions (Table 4, Entry 6)

To a mixture of acetylene **7c** (264 mg, 0.75 mmol), azide **8a** (105 mg, 0.79 mmol) and *t*-BuOH (3.5 mL) a solution of Na-ascorbate (30 mg, 0.15 mmol) in water (2.5 mL), and a solution of $CuSO_4 \cdot 5H_2O$ (4 mg, 0.02 mmol) in water (1 mL) were added. The reaction mixture was stirred in darkness at room temperature for 9 h. Then a solution of Na-ascorbate (89 mg, 0.45 mmol) in water (1 mL), and a solution of $CuSO_4 \cdot 5H_2O$ (11 mg, 0.044 mmol) in water (1 mL) and *t*-BuOH (2 mL) were added. The reaction mixture was stirred for additional 20 h. The resulting sticky sediment that formed in the course of the reaction was dissolved by addition of acetonitrile (3 mL) to the reaction mixture. The reaction mixture was stirred for additional 19 h. Although the azide and acetylene coupling partners were still present in the reaction mixture, as judged by TLC analysis, the reaction was stopped by the addition of water (50 mL) and extracted with chloroform (4 × 30 mL). The combined organic layers were dried (Na₂SO₄), filtered, and evaporated to dryness. The residue was dissolved in chloroform and subjected to silica gel (35 g) column chromatography using 67% ethyl acetate in petroleum ether as eluent, affording regenerated starting acetylene **7c** (48 mg, 0.14 mmol, 18%) and product **2d** (295 mg, 0.61 mmol, 81%).

3.12. Synthesis of Bis-Triazole 2d by Employing t-BuOH/Water/CuSO₄·5H₂O/L-Ascorbic Acid Conditions (Table 4, Entry 7)

To a mixture of acetylene **7c** (264 mg, 0.75 mmol) and azide **8a** (105 mg, 0.79 mmol) a solution of L-ascorbic acid (13 mg, 0.074 mmol) and CuSO₄·5H₂O (2 mg, 0.008 mmol) in water (3.5 mL), and *t*-BuOH (3.5 mL) were added. The reaction mixture was stirred in darkness at room temperature. After 8.5 h and 22 h of stirring additional portions of L-ascorbic acid/CuSO₄·5H₂O/water/*t*-BuOH (40 mg, 0.23 mmol/6 mg, 0.02 mmol/1 mL/1 mL and 53 mg, 0.3 mmol/7.5 mg, 0.03 mmol/1 mL/1 mL, respectively) were added. Although after stirring for additional 23 h (total reaction time 45 h), TLC analysis indicated the presence of azide and acetylene starting compounds, the heterogeneous reaction mixture (a sticky sediment was formed) was diluted with water and extracted with chloroform (5 × 50 mL). The combined organic layers were dried (Na₂SO₄), filtered, and evaporated to dryness. The residue was dissolved in chloroform (5 mL) and subjected to silica gel (35 g) column chromatography using 33% ethyl acetate in petroleum ether as eluent, affording regenerated starting acetylene **7c** (114 mg, 0.32 mmol, 43%) and product **2d** (165 mg, 0.34 mmol 45%).

3.13. 3-Azido-3-methyl-1-(prop-2-yn-1-yl)Quinoline-2,4(1H,3H)-Dione (9a) (Scheme 3)

A mixture of the azide **5a** (649 mg, 3.0 mmol) and potassium carbonate (1.24 g, 9 mmol) in DMF (15 mL) was stirred at room temperature in darkness for 40 min. Propargyl bromide (**6c**, 80% solution in toluene, 669 mg, 4.5 mmol) diluted with DMF (7 mL) was added dropwise under stirring during 1 min. The reaction mixture was stirred for 6 h, during which time it turned yellow, diluted with cold water (200 mL) and extracted with chloroform (5 \times 50 mL). The combined organic layers were dried (Na₂SO₄), filtered, and evaporated to dryness. Trace amounts of DMF were removed by five

subsequent co-destilations *in vacuo* at 50 °C with toluene (30 mL). The residual yellow oil was dissolved in chloroform (5 mL) and chromatographed on column silica gel (35 g) using chloroform as eluent, affording product **9a** (717 mg, 2.82 mmol, 94%, dried *in vacuo* to constant weight) as off-white oily material, that was pure by TLC ($R_f = 0.57$; chloroform); ¹H NMR (500 MHz, CDCl₃) δ 1.79 (s, 3H), 2.29 (dd, 1H, *J* = 2.5, 2.5 Hz), 4.67 (dd, 1H, *J* = 17.8, 2.5 Hz), 4.98 (dd, 1H, *J* = 17.8, 2.5 Hz), 7.26 (ddd, 1H, *J* = 7.7, 7.4, 0.8 Hz), 7.35 (d, 1H, *J* = 8.3 Hz), 7.71 (ddd, 1H, *J* = 8.3, 7.4, 1.7 Hz), 8.02 (dd, 1H, *J* = 7.7, 1.7 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 23.6, 32.7, 70.7, 73.4, 77.1, 115.8, 119.6, 124.4, 129.0, 136.9, 140.8, 169.1, 191.1; IR (cm⁻¹): ν 3241, 2980, 2138, 2107, 1711, 1678, 1603, 1471, 1383, 1366, 1305, 1285, 1260, 1218, 762; HRMS (ESI+): m/z calcd for C₁₃H₁₁N₄O₂⁺ [M + H]⁺ 255.0877, found 255.0877; calcd for C₁₃H₁₁N₂O₂⁺ [M - N₂ + H]⁺ 227.0815, found 227.0814.

3.14. Synthesis of Triazole 7a from Phenylacetylene (6a) and Compound 9a (Scheme 3)

A mixture of compound **9a** (286 mg, 1.13 mmol), phenylacetylene (**6a**) (230 mg, 2.25 mmol), CuSO₄ 5H₂O (28 mg, 0.11 mmol) and granular copper (143 mg, 2.25 mmol) in DMF (5 mL) was stirred in darkness at room temperature for 60 min. To the resulting brown-green suspension (NH₄)₂CO₃ (324 mg, 3.38 mmol) and water (3 mL) were added and stirring was continued for 10 min. The resulting mixture was diluted with 10% ethanol in chloroform (10 mL). The organic layer was separated and the aqueous layer was extracted with chloroform (3 × 10 mL). The combined organic layers were passed through a narrow (1 cm in diameter) column of silica gel (13 g) and the column was subsequently washed with 10% ethanol in chloroform (210 mL) using overpressure to the top of the column. The yellow eluate was washed with saturated aqueous NH₄Cl (1 × 50 mL) and distilled water (1 × 50 mL), dried (Na₂SO₄), filtered, and evaporated to dryness. Trace amounts of DMF were removed by five subsequent co-destilations *in vacuo* at 50 °C with toluene (40 mL). The residue was chromatographed on a column of silica gel (30 g) using 38% ethyl acetate in hexane. The resulting white solid (88 mg) was crystallized from benzene affording triazole **7a** (66 mg, 0.19 mmol, 16%), which was identified with the compound **7a** described above.

3.15. 3-Azido-1-((1-Benzyl-1H-1,2,3-Triazol-4-yl)Methyl)-3-Methylquinoline-2,4(1H,3H)-Dione (**10a**) (Scheme 3)

A mixture of acetylene 9a (254 mg, 1.0 mmol), (azidomethyl)benzene (8a) (266 mg, 2.0 mmol), CuSO₄·5H₂O (25 mg, 0.1 mmol) and granular copper (127 mg, 2.0 mmol) in DMF (10 mL) was stirred at room temperature for 21 h. Then (NH₄)₂CO₃ (288 mg, 3.0 mmol) and water (3 mL) were added and the stirring was continued for 10 min. The resulting mixture was poured into a narrow (1 cm in diameter) column of silica gel (13 g). The organic portion was eluted with 10% ethanol in chloroform (190 mL). The yellow eluate was washed with saturated aqueous NH₄Cl (50 mL) and water (50 mL), dried (Na₂SO₄), filtered, and evaporated to dryness. Trace amounts of DMF were removed by six subsequent co-destilations in vacuo at 50 °C with toluene (30 mL). The residue was dissolved in chloroform (5 mL) and chromatographed on silica gel (35 g) column using gradually 38% and 50% ethyl acetate in petroleum ether as mobile phase, affording product **10a** (164 mg, 0.42 mmol, 42%) as a white solid, m.p. 42–47 °C; $R_f = 0.21$ (38% ethyl acetate in petroleum ether); ¹H NMR (500 MHz, CDCl₃) δ 1.73 (s, 3H), 5.20 (d, 1H, J = 15.6 Hz), 5.31 (d, 1H, J = 15.6 Hz), 5.45 (d, 1H, J = 14.8 Hz), 5.49 (d, 1H, J = 14.8 Hz), 7.16–7.28 (m, 3H), 7.32–7.39 (m, 3H), 7.54 (s, 1H), 7.67 (ddd, 1H, J = 8.3, 7.4, 1.6 Hz), 7.77 (d, 1H, J = 8.4 Hz), 7.96 (dd, 1H, J = 7.7, 1.5 Hz); ¹³C NMR (126 MHz, CDCl₃) δ 23.6, 39.1, 54.5, 70.6, 116.6, 119.5, 123.5, 124.3, 128.3, 128.8, 129.0, 129.3, 134.3, 137.1, 141.4, 143.0, 169.8, 191.3; IR (cm⁻¹): v 3137, 3033, 2980, 2106, 1713, 1676, 1602, 1489, 1469, 1379, 1336, 1279, 1223, 765, 724; HRMS (ESI+): m/z calcd for C₂₀H₁₈N₇O₂⁺ [M + H]⁺ 388,1516, found 388.1514. Anal. Calcd for C₂₀H₁₇N₇O₂ (387.39): C, 62.01; H, 4.42; N, 25.31%. Found: C, 61.74; H, 4.77; N, 25.15%.

4. Conclusions

We have developed a methodology for accessing bis(1,2,3-triazole) functionalized quinoline-2,4-diones in which the triazole heterocycles are present in substituents at positions 1 and 3 of the quinoline scaffold. Preliminary investigation has revealed that these compounds are potential multidentate ligands for arene-ruthenium.

Supplementary Materials: The following are available online: ¹H NMR and ¹³C NMR spectra of all new compounds.

Author Contributions: D.M. performed the experiments. The manuscript was prepared through the contributions of R.K., M.G., D.U., S.K., and J.K.

Funding: The authors acknowledge the financial support from (internal grants No. IGA/FT/2018/007, funded from the resources of specific university research) and the Slovenian Research Agency (Research Core Funding Grant P1-0230, Project J1-8147, and Project J1-9166).

Acknowledgments: Tereza Dostálová and Lovro Kotnik participated in this study in their undergraduate projects. Their contributions are gratefully acknowledged.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Košmrlj, J. (Ed.) *Click Triazoles, Topics in Heterocyclic Chemistry*, 1st ed.; Springer: Berlin, Germany, 2012; Volume 28, ISBN 978-3-642-29429-7.
- 2. Crowley, J.D.; McMorran, D.A. 'Click-Triazole' coordination chemistry: Exploiting 1,4-disubstituted 1,2,3-Triazoles as ligands. In *Topics in Heterocyclic Chemistry*, 1st ed.; Košmrlj, J., Ed.; Springer: Berlin, Germany, 2012; Volume 28, pp. 31–83.
- 3. Schweinfurth, D.; Deibel, N.; Weisser, F.; Sarkar, B. Getting new ligands with a click. *Nachr. Chem.* **2011**, *59*, 937–941. [CrossRef]
- 4. Lee, S.; Flood, A.H. Binding Anions in Rigid and Reconfigurable Triazole Receptors. In *Topics in Heterocyclic Chemistry*, 1st ed.; Košmrlj, J., Ed.; Springer: Berlin, Germany, 2012; Volume 28, pp. 85–108.
- 5. Watkinson, M. Click Triazoles as Chemosensors. In *Topics in Heterocyclic Chemistry*, 1st ed.; Košmrlj, J., Ed.; Springer: Berlin, Germany, 2012; Volume 28, pp. 109–136.
- 6. Schweinfurth, D.; Hettmanczyk, L.; Suntrup, L.; Sarkar, B. Metal complexes of click-derived triazoles and mesoionic carbenes: Electron transfer, photochemistry, magnetic bistability, and catalysis. *Z. Anorg. Allg. Chem.* **2017**, *643*, 554–584. [CrossRef]
- Tornøe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on Solid Phase: [1-3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides. *J. Org. Chem.* 2002, 67, 3057–3064. [CrossRef] [PubMed]
- Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective "Ligation" of Azides and Terminal Alkynes. *Angew. Chem.* 2002, 114, 2708–2711. [CrossRef]
- Kafka, S.; Hauke, S.; Salcinovic, A.; Soidinsalo, O.; Urankar, D.; Kosmrlj, J. Copper(I)-Catalyzed [3 + 2] Cycloaddition of 3-Azidoquinoline-2,4(1*H*,3*H*)-diones with Terminal Alkynes. *Molecules* 2011, 16, 4070–4081. [CrossRef]
- 10. Proisl, K.; Kafka, S.; Košmrlj, J. Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds. *Curr. Org. Chem.* **2017**, *21*, 1949–1975. [CrossRef]
- 11. Bolje, A.; Urankar, D.; Košmrlj, J. Synthesis and NMR Analysis of 1,4-Disubstituted 1,2,3-Triazoles Tethered to Pyridine, Pyrimidine, and Pyrazine Rings. *Eur. J. Org. Chem.* **2014**, 8167–8181. [CrossRef]
- 12. Bolje, A.; Košmrlj, J. A Selective Approach to Pyridine Appended 1,2,3-Triazolium Salts. *Org. Lett.* **2013**, *15*, 5084–5087. [CrossRef] [PubMed]
- Perczel, A.; Atanasov, A.G.; Sklenář, V.; Nováček, J.; Papoušková, V.; Kadeřávek, P.; Žídek, L.; Kozłowski, H.; Watły, J.; Hecel, A.; et al. The Eighth Central European Conference "Chemistry towards Biology": Snapshot. *Molecules* 2016, *21*, 1381. [CrossRef] [PubMed]

- Kafka, S.; Proisl, K.; Kašpárková, V.; Urankar, D.; Kimmel, R.; Košmrlj, J. Oxidative ring opening of 3-hydroxyquinoline-2,4(1*H*,3*H*)-diones into *N*-(α-ketoacyl)anthranilic acids. *Tetrahedron* 2013, 69, 10826–10835. [CrossRef]
- 15. Stadlbauer, W.; Laschober, R.; Lutschounig, H.; Schindler, G.; Kappe, T. Halogenation reactions in position 3 of quinoline-2,4-dione systems by electrophilic substitution and halogen exchange. *Monatsh. Chem.* **1992**, 123, 617–636. [CrossRef]
- 16. Kafka, S.; Klásek, A.; Polis, J.; Košmrlj, J. Syntheses of 3-Aminoquinoline-2,4(1*H*,3*H*)-diones. *Heterocycles* **2002**, *57*, 1659–1682. [CrossRef]
- Meldal, M.; Tornøe, C.W. Cu-Catalyzed Azide–Alkyne Cycloaddition. *Chem. Rev.* 2008, 108, 2952–3015. [CrossRef] [PubMed]
- Buckley, B.R.; Heaney, H. Mechanistic Investigations of Copper(I)-Catalysed Alkyne–Azide Cycloaddition Reactions. In *Topics in Heterocyclic Chemistry*, 1st ed.; Košmrlj, J., Ed.; Springer: Berlin, Germany, 2012; Volume 28, pp. 1–30.
- 19. Kimmel, R.; Kafka, S.; Košmrlj, J. Selective formation of glycosidic linkages of *N*-unsubstituted 4-hydroxyquinolin-2-(1*H*)-ones. *Carbohydr. Res.* **2010**, 345, 768–779. [CrossRef] [PubMed]
- 20. Urankar, D.; Košmrlj, J. Concise and Diversity-Oriented Synthesis of Ligand Arm-Functionalized Azoamides. *J. Comb. Chem.* **2008**, *10*, 981–985. [CrossRef] [PubMed]
- Iha, R.K.; Wooley, K.L.; Nyström, A.M.; Burke, D.J.; Kade, M.J.; Hawker, C.J. Applications of Orthogonal "Click" Chemistries in the Synthesis of Functional Soft Materials. *Chem. Rev.* 2009, 109, 5620–5686. [CrossRef] [PubMed]
- Urankar, D.; Pinter, B.; Pevec, A.; De Proft, F.; Turel, I.; Košmrlj, J. Click-Triazole N2 Coordination to Transition-Metal Ions Is Assisted by a Pendant Pyridine Substituent. *Inorg. Chem.* 2010, 49, 4820–4829. [CrossRef] [PubMed]
- 23. Sá, M.M.; Ramos, M.D.; Fernandes, L. Fast and efficient preparation of Baylis–Hillman-derived (*E*)-allylic azides and related compounds in aqueous medium. *Tetrahedron* **2006**, *62*, 11652–11656. [CrossRef]
- 24. Boyer, J.H.; McCane, D.I.; McCarville, W.J.; Tweedie, A.T. Pyrido-2,3-furoxane. J. Am. Chem. Soc. 1953, 75, 5298–5300. [CrossRef]

Sample Availability: Samples of all compounds are available from the authors.



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).